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Chapter One: 
General Introduction 
 
 
 
1.1 The Aim of the Research 
Antibodies can be ectopically expressed as secreted proteins in cells that do 
not normally express them to interfere with extracellular antigens and/or as 
intracellular proteins targeted to different intracellular compartments to 
inhibit intracellular gene products: this has lead to an effective protein 
knock-out technology. 
Expression of antibodies inside cells has been used successfully to ablate 
protein function.  
The performance of antibodies that are intracellularly expressed is however 
somewhat unpredictable because the reducing environment of the cell 
cytoplasm in which they are forced to work prevents some antibodies, but 
not others, to fold properly. 
For this reason, a selection procedure for the isolation of antibodies able to 
fold correctly and to bind antigens under condition of intracellular 
expression would be highly desirable. The development of this novel 
selection procedure could exploit methods to monitor intracellular protein –
protein interactions, for instance the yeast two-hybrid technology. 
Such a system would greatly facilitate the isolation of candidate antibodies 
for intracellular antibody down-stream applications in the system of 
interest, and would lend itself to the development of cell-based high-
throughput screening procedures in functional genomics applications. 
In view of this, the creation of a new technology that allows the isolation of 
intracellular scFv fragments, based on their ability to bind antigen under 
conditions of intracellular expression has become an important goal both 
for functional genomics and for gene therapy, to fulfill the requirement of 
antibodies with improved thermodynamic stability and solubility 
properties. 
 
 
1.2 Results 
The following chapters will describe all the steps taken in order to achieve 
the final goal: the development of the intrabody trap technology (ITT), an 
in vivo selection and assay procedure for functional intracellular antibodies 
using a two-hybrid approach. 
In the first part of the project we find that several characterized antibodies 
can bind their target antigen in eukaryotic cells when expressed in the two-
 2 
hybrid format and we have been able to isolate intracellular binders from 
panels of scFv, all of which can bind antigen in vitro. Furthermore, we 
showed a model selection in which a single chain scFv was isolated from a 
mixture of half a million clones, indicating that this is a robust procedure 
that should facilitate isolation of intrabody specificity from complex 
mixtures.  
The results form the basis of the “intrabody trap technology”, whereby 
many different, specific and functional antibodies can be isolated in vivo 
under condition of intracellular expression. 
The second part of the thesis reports the demonstration that ITT can be 
effectively applied to the de novo selection of functional intrabodies, by 
performing a real selection from polyclonal scFv fragments partially 
enriched from a large naive phage library by antigen panning. The 
experimental procedure described in this thesis has allowed the selection of 
intrabodies against a protein antigen involved in Alzheimer’s disease (AD), 
the microtubule associated protein tau, the main components of the paired 
helical filaments (PHFs), found in neurofibrillary lesions in AD brains. In 
particular the aim of the work was to isolate scFv fragments against a tau 
fragment, which displays apoptotic capacity in different cellular context.  
 
 
 
In order to fully appreciate the different aspects of the experimental works 
and its underlying strategies the first chapter includes some theoretical 
paragraphs that provide a general background to the work performed. 
 
 
 
 
1.3 Functional Genomics 
 
 
1.3.1 From Genes and Proteins to Genomes and Proteomes  
The completion of the sequences of the genomes of several organisms is a 
watershed for the new science of genomics (Smith et al., 1996).  
Genomics refers to the analysis of the genomes and functional genomics is 
a component of this field that uses global approaches to understand the 
functions of genes and proteins.  
Functional genomics is expected to predict gene function of genes 
identified by large-scale sequencing efforts that come from different 
genome projects in the public domain, biotechnology sectors, and 
pharmaceutical gene-discovery efforts and this is providing a framework to 
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allow the investigation of biological processes by the use of comprehensive 
global approaches. 
 The goal of functional genomics is to elucidate some fundamental 
questions of human life: 
 
• How does the exact sequence of human DNA differ between 
individuals? 
• What are the differences that result in disease or predisposition to 
disease? 
• How do proteins collaborate to perform the tasks required for life? 
• Which genes are used under which circumstances? 
• How do this differential gene expression results in different types of 
cells and tissues in a multicellular organism? (Fields et al., 1999)  
• What are the gene and the related protein functions in normal and in 
disease states? (Dyer et al., 1999) 
The ultimate question of functional genomics is:  
• What is the specific role of each protein synthesized by different 
organisms? 
 
In the past, molecular biologists considered the coordination of cellular 
processes largely as the synthesis of many individual reactions. Yet it is 
now thought that many of these processes are performed and regulated by 
multiprotein complexes, otherwise termed “protein machines” (Alberts & 
Miake-Lye, 1992), which are helped together and exert their function 
through specific protein-protein interaction. With improvements in 
technology, new tools have become available to study the complex 
interactions that occur in biological systems. It is now accepted that the 
best approach is not the study of individual molecules, but the examination 
on the large-scale and high-throughput of the genes and the gene products 
of an organism, with the aim of understanding how that organism is 
assembled or how it operates (Clark, 1999) (Wiley, 1998). 
One approach to reconstructing cellular machinery and inferring function is 
to identify protein interactions, because proteins engaged in common task 
(such as a signaling cascade or a macromolecular complex) often contact 
one another.  
A number of conventional approaches to studying protein-protein 
interactions include biochemical techniques that are powerful tools for 
investigating protein complexes but are not very suitable for high 
throughput screening. The yeast two-hybrid system, originally developed to 
monitor protein-protein interactions between two given proteins (Fields & 
Song, 1989) was adapted to a genomic format allowing all proteins from an 
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organism to be assayed for interactions with all other proteins from that 
organism.  
Interaction traps, such as two-hybrid system and modification of this 
system, are commonly used for the identification of interacting partners in 
vivo (Lander, 1996) and its use in high throughput screening applications 
allows the rapid and efficient screening of large numbers of potential 
interacting cDNA (Fromont-Racine et al., 1997) (Flajolet et al., 2000) or 
peptides. 
Genome-wide two-hybrid approaches offer insight into novel interactions 
between proteins involved in the same biological function. 
Nowadays it is possible to study molecular mechanism globally in the 
context of complete sets of genes, rather than analyzing genes individually 
(Walhout et al., 2000). For example, DNA microarrays and chips, which 
use high-density two-dimensional arrays of chemically synthesized 
molecules on glass surface can be used to monitor simultaneously the 
expression of nearly all genes of an organism or can also identify genes 
expressed preferentially in normal or, for example, tumor tissue. 
Recently, microarray technology is also being applied for genome-wide 
two-hybrid approaches (Uetz et al., 2000). 
The ability to carry out a comprehensive genetic analysis of an organism 
becomes more limited and difficult as the complexity of the organism 
increases. Complex organisms are likely to have not only more genes than 
simple organisms but also more elaborate networks of interactions among 
those genes. 
The development of technologies to systematically disrupt protein 
networks at the genomic scale would greatly accelerate the comprehensive 
understanding of the cell as molecular machinery and will represent a 
fundamental approach for functional genomics. 
In general, the classical approach to solve the problem of identifying the 
function of the gene is to inactivate the gene and studies what effects this 
has. 
The function of a gene can, in principle, be inactivated at any of several 
levels. 
The next paragraph will discuss and compare current methods of inhibiting 
gene function. 
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1.4 Genotypic and Phenotypic Knock-Out Methods 
for Functional Genomic 
 
1.4.1 Gene Knock-Out by Homologous Recombination 
In some organisms a wild-type gene can be replaced by a mutant version of 
the same gene. Gene targeting is the use of homologous recombination 
(HR) between the target genomic locus and DNA introduced into the cells 
to make defined alterations into the genome of living cells.  
The principal virtue of this method is that the gene function is completely 
destroyed, but the present technique is only applicable at few organisms, 
including Aspergillus (Miller et al., 1985), Dictyostelium (De Lozanne & 
Spudich, 1987), yeast (Scherer & Davis, 1979), (Russell & Nurse, 1986), 
mouse (Koller & Smithies, 1992) and also in Drosophila (Rong & Golic, 
2000). 
A major obstacle to the success of this technique is the relative inefficiency 
of the targeting process in most mammalian cells. 
Gene disruption by homologous recombination only works efficiently in 
embryonic stem (ES) cells. These early embryo-derived cell lines can be 
manipulated in tissue culture and then returned to the embryo where they 
participate in the normal development of the chimeric mouse (Joyner, 
1991). This approach has lead to the explosion of knock-out mice 
technology. The gene knock-out approach allow the analysis of diverse 
aspects of gene function in vivo. 
To improve the efficiency and accuracy of homologous recombination 
events many new approaches have been employed, including artificial 
double-strand breaks in both the exogenous and chromosomal DNA, a 
transient overproduction of an inactive recombinase and of the bacterial 
RecA or mammalian RecA-like proteins in mammalian cell nuclei 
(Lanzov, 1999). 
Although this technology has broad potential for fundamental research 
because of the obvious advantage of the absolute knock-out of the gene in 
homozygous individuals, the possible lack of spatio-temporal control over 
the gene knock-out can pose problems of lethality or trigger the onset of 
compensatory mechanisms. The interpretation of results observed after 
development of the organism can therefore be more difficult. 
Recent advances on “conditional” gene targeting technology, combined to 
the use of prokaryotic recombinase proteins with restricted transcriptional 
control has improved gene inactivation in a defined tissue and at a specific 
time point during development or adulthood, thereby extending the 
sophistication and potential of this technology (Muller, 1999). 
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Fig.1.1 Disruption of a gene, by gene targeting 
Disruption of hprt by gene targeting with (A) a sequence replacement-targeting vector 
or (B) a sequence insertion-targeting vector. Vectors of both classes contain hprt 
sequences interrupted in the eight exon with neo gene. With the sequence replacement 
vector, after homologous pairing between the vector and genomic sequence, a 
recombination event replaces the genomic sequence with vector sequences containing 
neo. Sequence insertion vectors are designed such that the ends of the linearized vector 
lie adjacent to one another on the hprt map. Pairing of such a vector with its genomic 
homologue, followed by recombination at the double-strand break, results in insertion 
of the entire vector into the endogenous gene. This produces a duplication of a portion 
of hprt. (Capecchi, 1989) 
 
 
1.4.2 Dominant Negative Mutations 
In this strategy, the cloned gene is altered so that it encodes a mutant 
product capable of inhibiting the wild-type gene product in a cell, thus 
causing the cell to be deficient in the function of that gene product. Such a 
mutation is “dominant” because its phenotype is manifested in the presence 
of the wild-type gene, and as it inactivates the wild-type gene function it is 
referred to as a “dominant negative” mutation. 
The inhibitory variants of the wild-type product can be designed because 
proteins have multiple functional sites that can be mutated independently.  
The dominant negative mutant proteins can retain an intact and functional 
subset of the domains of the parent wild-type protein, but have the 
complement of this subset either missing or altered so as to be non-
functional. 
There are large amounts of published data concerning the use of dominant-
inhibitory proteins: in particular many reports using Ras mutants to 
suppress the activation of Ras and Ras-related GTP-hydrolyzing enzymes, 
or GTPases, has been published (Feig & Cooper, 1988) (Feig, 1999). 
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This method however, is not general and can only be applied with success 
in some cases. The success of this strategy requires a detailed study of 
structural and functional domains on the target protein and requires proper 
folding of the mutant protein compared to the wild-type protein. 
Moreover, the properties shown using such dominant negative product 
suggest that there are limitations to the possible interpretations of the 
obtained results. The overproduction of an inactive product might have the 
opposite effect of increasing the activity of the wild-type protein especially 
when the defective form of the protein titrates a cellular inhibitor. 
 
 
 
 
 
 
 
 
 
 
 
Fig.1.2 (A) Dominant negative mutants. Inhibitory polypeptides that interfere 
with the function of dimeric proteins. A dominant negative version of a dimeric protein 
may lead to an inactive dimer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1.2 (B) Dominant negative mutants. Inhibitory polypeptide that interfere 
with function of monomeric proteins  a) example of a monomeric enzyme that is able to 
phosphorylates  its substrate b) the mutant form of that enzyme that has inactivated the 
catalytic site of the enzyme c) the mutant enzyme act as a competitive inhibitor of the 
wild type form (Herskowitz, 1987) 
 MONOMERS MUTANTS 
HETERODIMERS 
Wild type 
HOMODIMERS 
Active Inactive 
a) Wild type 
P
b) Mutant 
c) Wild type and excess of mutant 
P 
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1.4.3 RNA-based methods 
Experimental introduction of RNA into cells can be used in certain 
biological system to interfere with the function of an endogenous gene, 
ultimately depending on some form of antisense mechanism based on 
hybridization between the injected RNA and endogenous messenger RNA 
transcripts. 
This approach might be particularly useful in species that were previously 
considered not to be amenable to genetic analysis. 
There are four RNA-based approaches that has attracted much attention 
during last ten years: 
• sense and antisense RNA 
• antisense oligodeoxynucleotides (ODN) 
• ribozymes 
• double-stranded RNA-mediated interference (RNAi) or “quelling” 
The expression of DNA encoded antisense RNA preparations by gene 
transfer methods is postulated to prevent the expression of the 
corresponding protein by hybridizing with the complementary nucleic acid 
molecules. 
It was shown that sense and antisense RNA preparations are each sufficient 
to cause inhibition of target genes in C.elegans (Fire et al., 1991). Their 
effect can persist well into further generation, even though many 
endogenous RNA transcripts are rapidly degraded in the early embryo. 
The unpredictable secondary and tertiary RNA structure, together with 
stability and expression levels and optimal length and locations of antisense 
RNA, are the most important limitation of this approach. 
The promising results obtained with this technology seem to be contributed 
by the interference of some molecules with double-stranded character 
rather then the activity of individual strands (Fire et al., 1998).  
Antisense reagents can also be designed as small oligodeoxynucleotides 
(ODN).  
Antisense oligonucleotides affect cells by hybridizing to target sequences 
within mRNA, thus destabilizing the target mRNA and ultimately 
decreasing translation to protein. 
Antisense effects of ODNs in mammalian cells have been reported in 
numerous tissue culture experiments and in several in vivo studies 
(Wagner, 1994). Several chemical modifications have been shown to 
improve the performance of the antisense ODN. 
However, the phosphorothioates (PSs), which are the major antisense 
oligonucleotides considered for clinical therapeutic trial, induce significant 
non-sequence-specific effects at both the molecular and supramolecular 
level. 
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Furthermore, antisense oligonucleotides have a number of side effects 
related to: 
• degradation: ODNs are degraded both intra- and extracellularly by 
serum and intracellular nucleases  
•  inability to enter the target cell: oligos are polyanionic molecule 
and cannot passively diffuse across cell membranes. The use of 
phosphodiester (PO) oligos can avoid this problem because they can 
be internalized within cells 
• exocytosis. Oligos undergo exocytosis and are not retained by the 
target cell: the origin of this process and its effects on antisense 
inhibition are unknown 
• ability to locate their targets. Intracellular targets for oligos (such as 
mRNA, pre-mRNA and genomic DNA) are protein bound, and 
many sites are probably not accessible for Watson-Crick base 
pairing 
• non-specific binding with macromolecules. It has been shown that 
phoshorothioates bind to heparin-binding proteins with very high 
affinity and with cell surface proteins, producing biological 
consequences that may be confused with antisense inhibition 
• last but not least, many studies with antisense lack appropriate 
controls making it difficult to judge the real effectiveness. 
The potential of the antisense biotechnology with the benefits of 
improvements by chemical modifications are enormous but the unbalance 
between the number of real successful antisense inhibition and the putative 
reports of success is still an open question (Stein, 1999) (Stein & Cheng, 
1993).  
The term “ribozyme” has been introduced to described RNA molecules 
with enzymatic activity. The potential application of ribozymes as gene 
inhibitors, where a messenger RNA encoding a harmful protein would be 
intercepted and cleaved, is a fruitful area of research. 
A variety of ribozyme catalytic motifs have been identified, all of which 
catalyze reaction on RNA substrate. These reactions involve site-specific 
strand scission and ligation reactions.  
In general ribozymes require for cleavage a specific set of three 
nucleotides at the cleavage site; GUC is the triplet most efficiently cleaved 
by hammerhead ribozymes (Sigurdsson & Eckstein, 1995). 
The first forms of catalytic RNA were discovered in the cellular RNA-
splicing and processing machinery in the form of self-splicing group I 
introns and precursor tRNA-processing RNase P; other naturally occurring 
catalytic RNAs was subsequently discovered including group II introns, 
hammerhead ribozyme, hairpin ribozyme, hepatitis delta virus ribozyme 
and tRNA
Phe 
(Scott & Klug, 1996).  
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The self-catalyzed RNA cleavage reactions share a requirement for 
divalent metal ions and neutral or higher pH (Haseloff & Gerlach, 1988). 
One of the major limitations of this approach is the instability of RNA. 
The cleavage of ribozyme-RNA by ribonuclease can be avoided by 
functional-group modifications (substitution of the pyrimidines of the 
ribozyme with their 2’-fluoro derivatives, modifications to the 2’-O-
methyl-groups, 2’-O-allyl-groups and 2’-deoxy-groups) at the 2’-site 
(Sigurdsson & Eckstein, 1995). 
In general, the limitations shown before for antisense oligonucleotides 
remain the same for ribozymes with the addition of an improved 
selectivity of the ribozyme for its target RNA that will severely affect 
ribozyme efficiency when base-pairing mismatches or mutations adjacent 
to the site of cleavage occur. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1.3 Ribozyme verus antisense-RNA-mediated inhibition of mRNA 
expression. The targeted messenger base pairs with either the antisense RNA (a) or 
ribozyme (b). The antisense inhibitory mechanisms may block cellular functions such 
as splicing, transport from the nucleus to the cytoplasm, or translation. In addition, the 
antisense-mRNA hybrid may activate cellular double-stranded ribonucleases or 
double-strand-specific RNA-modifying enzymes. In either case, the antisense acts 
stoichiometrically. The ribozyme interacts with the cleavage site by base pairing, 
cleaves the target and dissociates from the cleaved products; it can then recycle to 
cleave additional target RNAs. The ribozyme generates a 2’,3’-cyclic phosphate and 
5’-OH; this functionally destroys the target RNA (Rossi, 1995). 
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Another recent RNA-based approach for studying gene function by 
inhibition of RNA is the double-stranded RNA-mediated interference 
(RNAi) of gene expression.  
This method has rapidly become a widely used method facilitating reverse 
genetic studies in Cenorhabditis elegans (Ketting & Plasterk, 2000), 
Neurospora crassa (Cogoni & Macino, 1999), Arabidopsis thaliana 
(Dalmay et al., 2000), Drosophila (Clemens et al., 2000), E.coli 
(Tchurikov et al., 2000) and mice (Wianny & Zernicka-Goetz, 2000). 
In this process double strand RNA (dsRNA) silences the expression of 
endogenous genes after they have been transcribed by inducing sequence 
specific degradation of homologous messenger RNA molecules. 
By exploiting post-transcriptional gene silencing (PTGS), originally called 
“co-suppression” by plant biologist, “RNA interference” by those studying 
worms and flies, and “quelling” by researchers working with fungi, 
specific genes has been switched off in a variety of organisms, allowing to 
deduce gene functions. 
The mechanism by which dsRNA prevents target gene expression is not 
completely understood but it may represent a cellular defense against viral 
infection, or perhaps a post-transcriptional mechanisms for regulating gene 
expression in response to dsRNA formed from nuclear transcripts. 
The gene silencing induced by RNAi is reversible and thus does not 
appear to reflect a genetic change (Fire et al., 1998). 
There are several evidences that RNAi functions post-transcriptionally, 
including the fact that dsRNA corresponding to intron sequences does not 
produce RNAi and that dsRNA corresponding to exon sequences does not 
affect pre-mRNA levels (Tuschl et al., 1999). 
PTGS is more efficiently induced by transgenes designed to produce the 
dsRNA of a gene than by either sense or antisense RNA alone. 
RNAi has attracted considerable attention because it is a means of 
knocking-out the activity of specific genes, being particularly useful in 
species that were previously considered not to be amenable to genetic 
analysis. 
RNAi process is homology-dependent, and the sequences to be targeted 
for gene-specific RNAi should be carefully selected to avoid cross-
interferences between highly homologous sequences (Fire et al., 1998). 
It was shown, for example, that the injection in C.elegans of dsRNA 
specific for the 5’part of the gene encoding the body-wall muscle myosin 
heavy chain generate a lethal phenotype, whereas the injection of dsRNA 
corresponding to other part of the same gene generates the expected 
paralysis phenotype (Fire et al., 1998). 
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Fig.1.4 A model for RNAi/PTGS/quelling. The involvement of RNA-
dependent RNA polymerase (RdRP) has been shown in quelling by the characterization 
of the qde-1 mutant. Genetic work in C.elegans has identified the requirement of other 
genes (rde-1, mut-7), but there is no evidence that they exist in a complex. A model was 
also proposed by Fire and coworkers in which RNAi does not involve RdRP-dependent 
copying step (Bosher & Labouesse, 2000). 
 
The use of dsRNA adds to the tools available for studying gene function in 
many organisms. Although the effects of dsRNA-mediated interference are 
potent and specific, several limitations should be taken into account when 
designing RNA-interference-based experiments. 
First, interferences between several closely related genes and sequences of 
gene families should be carefully evaluated. Second, it is likely that some 
genes and cell types resist to RNA-mediated interference effects: it is still 
unknown what is the active mechanism that mediate the intracellular 
transport of dsRNA molecule. 
Third, what is the duration of the interference effect? The dilution of 
dsRNA through cell division should affect the expected interferences: it 
was shown that embrionically expressed genes are more easily knocked-
out than late-acting ones (Bosher & Labouesse, 2000) (Wianny & 
Zernicka-Goetz, 2000). 
One important limiting factor that was recently overcome in C.elegans is 
the inheritability of RNAi. The strategy of generating such inheritable 
dsRNA is based on the injection of a plasmid carrying inverted repeat so 
that the dsRNA is produced in vivo as a hairpin structure under the control 
of a strong, heat-shock-inducible promoter (Tavernarakis et al., 2000). The 
basis for this inheritance is still unclear but this approach seems to be a 
valid idea to investigate the late function of genes that can have also an 
essential early function.  
 13 
Furthermore, the use of this technique is very promising because it is 
simple (it requires the production of dsRNA from PCR product that has T7 
RNA polymerase binding sites at each end) and quick (knock-out results 
can be obtained within 2-3 days) (Clemens et al., 2000). Unfortunately, 
there are several limiting factors and mechanisms that still remain unclear: 
in particular the major limitation of this technique is that the target region 
of the RNA to be affected is still unpredictable a priori and need to be 
systematically scanned in order to locate the best RNAi site. 
 
 
1.4.4 Protein-Based Knock-Out 
Amongst the different types of molecules capable of inhibiting protein 
function through tight and specific binding are proteins themselves. 
Proteins are well suited for selection from combinatorial libraries where the 
binding partners can be retrieved easily by sequencing their corresponding 
DNA.  
There are two general protein-based approaches to inhibit the function of 
genes at the protein level:  
a) Peptide aptamers 
b) Intracellular antibodies 
 
a) Relatively small protein recognition modules that are widespread in 
several proteins often mediate the dynamic assembly of macromolecular 
complexes inside the cell. Each module family binds relatively short 
peptides with distinct chemical or structural characteristics. 
Combinatorial peptide libraries displayed on the coat of filamentous phage 
are largely used to select target peptide recognition specificity.  
One of the several alternatives to obtain peptide library is the design of a 
DNA library coding for random peptides inserted within a cellular carrier 
protein, which provides stability, conformational constraint, and targeting 
to a specific subcellular location. In general, the active site of thioredoxin 
A (TrxA) is chosen as carrier protein for random peptides because of its 
stability, ease of purification, and presence of a convenient restriction site 
in the region encoding the active site of the enzyme (Lu et al., 1995). 
Insertions into this site are tolerated, and tethering of both ends of the 
inserted peptide provides a degree of conformational constraint to the 
peptide not present when linear peptides have free ends (Blum et al., 2000).  
The TrxA was shown to serve as a scaffold for a combinatorial 20-mer 
peptide library fused to the activation domain of a yeast two-hybrid vector, 
also called “peptide aptamers” (Colas et al., 1996) and recently for the 
developing of the aptamer-based bacterial system (ABBIS), which allow 
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the conditional expression within bacterial cells of a random peptide library 
(Blum et al., 2000). 
Although interesting examples of application of this technology were 
reported in yeast, with the use of two-hybrid system, and E.coli, the 
feasibility of this system in other cell system and the generality, must be 
proven. In particular, after the selection of a binding peptide, its use as an 
inhibitor of protein function in the context of the cell is not strait forward 
nor general. 
 
b) Antibodies, the most popular class of molecules naturally designed as 
recognition molecules, provide a virtually unlimited repertoire of binding 
molecules for a wide range of applications. The use of ectopic antibody 
expression to inactivate gene products (Cattaneo & Neuberger, 1987) 
(Carlson, 1988) (Biocca et al., 1990) acts in a way that is very similar to 
that of the expression of a dominant negative mutant, because it is a 
dominant competitor, but its use is more general, since it relies on a class of 
diverse yet virtually similar inhibitor molecules. 
Antibodies, synthesized by the cell and targeted to a particular cellular 
compartment, can be used to interfere in a highly specific manner with cell 
growth and metabolism and gene function (Cattaneo & Biocca, 1997).  
The expression of antibodies inside the cell can be controlled at different 
levels: 
1) transcriptional: the expression of inhibitory antibody molecules 
occurs under the use of suitable promoters in any cell or tissue of 
interest. The use of specific regulated promoters may also provide 
potential control of gene expression not only in a dose-specific but 
also in a time-specific manner  
2) targeting: antibodies can be targeted to any cellular compartments by 
means of targeting signal sequences that can be inserted at different 
positions in the recombinant antibody 
The high affinity and selective-binding properties of intracellular 
antibodies, or intrabodies, can be useful to modulate cellular physiology 
and metabolism by a wide variety of mechanisms (Richardson & Marasco, 
1995) (Cattaneo & Biocca, 1997).  
For example: 
• they can block or stabilize macromolecular interactions 
• they can stabilize macromolecular interactions 
• they can modulate enzyme function by occluding an active site, 
sequestering substrate, or fixing the enzyme in an active or inactive 
conformation 
• they can divert proteins from their usual cellular compartments  
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• they can target specifically a post-transcriptionally modified version 
of a given protein (including heterodimerization) 
• they can specifically target the subcellular localization of a given 
protein 
• they can selectively target non-protein antigens The results obtained 
to date suggest that intracellular antibodies represent a powerful 
alternative to the other methods of gene inactivation previously 
discussed, and may represent the only option in some 
circumstances. 
The modular nature of the antibody, the completeness of antibody 
repertoires, the advance in antibody-library technology and the increasing 
knowledge in the cell and molecular biology of intracellular trafficking 
represent key points underlying the potential of the intracellular antibody 
technology. 
The efficacy of this strategy depends crucially on an efficient folding of 
antibody domains in ectopic environments. The requirements for an 
efficient folding of antibody domains depend on the particular cell 
compartment in which the antibodies are expressed. 
The next paragraph will describe recent advances in antibody engineering 
that allow the novo construction of antibodies and the selection of a desired 
antibody specificity by the screening of phage-display libraries, the 
limitation and the improvements of this technology to date, and the 
potentials of a designed selection schemes for the isolation of antibodies 
active in selected intracellular compartments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1.5 Targeting of intracellular 
antibodies. Illustration of how some of 
the known targeting signals can be 
exploited to redirect the intracellular 
trafficking of the antibodies in 
eukaryotic cells. For example, 
“intrabodies” can be directed to the 
nucleus, to the mitochondrion, to the 
plasma membrane and to the ER by 
means of targeting signals: see Table 
1.1. 
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Compartment Signal 
secretory MGWSCIILFLVATATGVHSQ (example) 
Hydrophobic leader sequence at N-terminal 
cytoplasmic MGWSKRRSSEETATAGVHSQ 
• Hydrophilic leader sequence at N-terminal 
None 
• Leader-less 
(Biocca et al., 1990) (Carlson, 1988) (Biocca et al., 1993) (Biocca et al., 1994) 
(Mhashilkar et al., 1995) (Maciejewski et al., 1995) (Persic et al., 1997) 
nuclear MGWSCPKKKRKVGGGTATVHSQ 
Nuclear localization sequence at N-terminal or C-terminal  
(Biocca et al., 1990) (Mhashilkar et al., 1995) (Persic et al., 1997) 
PKKKRKV: nuclear localization sequence of Large T-antigen of SV40 virus 
mitochondrial MSVLTPLLLRGLTGSARRLPVPRAK (amino terminal presequence of the 
mitochondrial enzyme cytochrome C oxidase) 
Presence of mitochondrial proteins at N-terminal (Biocca et al., 1995) 
 
Endoplasmic 
Reticulum (ER) 
Wild type leader sequence and SEKDEL (carboxy-terminal tetrapeptide sequence 
sufficient to cause retention in the ER) sequence at C-terminal 
(Biocca et al., 1995) (Graus-Porta et al., 1995) (Jost et al., 1994) 
ER lumen 
membrane 
Wild type leader sequence and µ chain transmembrane  
domain at C-terminal: NLWTTASTFIVLFLLSLFYSTTVTLF 
(Williams et al., 1990) 
Plasma membrane Wild type leader sequence and mutated µ chain transmembrane 
 domain at C-terminal: NLWVVAAVFIVLFLLSLFYSTTVTLFTMD  
(transmembrane domain) of T cell receptor, met receptor and PDGF receptor 
(Williams et al., 1990) (Eshhar et al., 1993) (Chesnut et al., 1996) 
 
Table 1.1 Peptide signals used for antibody targeting 
 
 
 
1.5 Intracellular Immunization 
 
1.5.1 Intrabodies: ectopic antibody expression to perturb gene 
products 
The humoral immune system produces a vast repertoire of antibodies of 
high affinity and specificity by gene rearrangements. This repertoire 
ensures that the vast majority of invading foreign antigens can be 
recognized and bound, despite the enormous variety of chemical and 
physical structures that these entities can represent. The prospect of being 
able to exploit or copy this phenomenon in the laboratory, generating 
molecules of high binding affinity against any chosen target, has lead to the 
development of new technologies that allow human antibody genes to be 
easily manipulated (Barbas et al., 1991) (Nissim et al., 1994) (Vaughan et 
al., 1996) (McCafferty et al., 1990).  
The advent of antibody engineering has opened up new avenues, including 
the possibility of producing high-affinity human antibodies against human 
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proteins. Antibodies derived from repertoires of variable regions displayed 
on the surface of filamentous phage (Winter & Milstein, 1991) (Winter et 
al., 1994) represent several advantages over classical monoclonals for 
many applications. The use of single-chain variable region fragments or 
scFv, in which the heavy- and the light-chain variable are synthesized as a 
single polypeptide and are separated by flexible linker peptide, is another 
element that has contributed to the success of recent antibody technology. 
Phage antibody technology does not require immunization of humans or 
animals and provides large and complete repertoires containing antibodies 
against any specificity of interest. Single-chain antibody fragments can be 
produced on a large scale by isolation from bacteria (Hoogenboom et al., 
1991) (Hoogenboom et al., 1992).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1.6 Structure of antibodies and of scFv fragment. An immunoglobulin 
is composed by two heavy chains and two light chains with the two antigen-binding 
regions made up of a heavy (VH) and light chain (VL). ScFv fragments are created by 
expressing the variable regions covalently joined by a polypeptide linker. 
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Fig.1.7 Phage Antibody Technology. Diagram showing one complete panning 
cycle 
 
 
 
The phage display technology, as a source of recombinant polyclonal 
repertoires of antigen binding antibodies, can be used for new selection 
schemes whereby intracellular expression and targeting of antibodies could 
be exploited. 
The antibody-based intracellular immunization strategy exploits the ectopic 
expression of recombinant antibodies to redirect antibodies to different 
intracellular compartments in order to inhibit the function of selected 
antigens in different biological systems (Cattaneo & Biocca, 1997) 
(Cattaneo & Biocca, 1999). 
Historically the first experiment to inhibit gene function using antibody 
proteins by microinjection was performed by Rita Levi-Montalcini and 
coworkers in 1966 (Levi-Montalcini & Angeletti, 1966). In that 
experiment, the injection of antibodies to the nerve growth factor in 
newborn rats was shown to induce cell death of sympathetic neurons. This 
experiment provided the formal proof that NGF was a growth factor 
required for the survival and differentiation of these cells. 
plate 
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From our point of view, that experiment demonstrated that antibodies can 
be used in a very effective way to study the function of protein in vivo. 
During subsequent years many other authors have used antibody injection 
inside cells to perturb gene function (Morgan & Roth, 1988) (Feramisco et 
al., 1985) (Hagag et al., 1986), but this has several limitations. The advent 
of recombinant antibody technology suggested that antibody expression in 
non-lymphoid cells could be achieved by gene transfer approaches, other 
than by antibody delivery. This led to the idea (Cattaneo & Neuberger, 
1987) (Carlson, 1988) (Biocca et al., 1990) that the technology of the 
ectopic expression of antibodies can have a great potential in gene therapy, 
in functional studies and also (as shown in this thesis) in functional 
genomics (Richardson & Marasco, 1995) (Biocca & Cattaneo, 1995) 
(Cattaneo & Biocca, 1997) (Visintin et al., 1999). 
The use of ectopic antibody expression exploits the virtually unlimited 
repertoire of the antibodies. This approach can allow the expression of 
inhibitory antibody molecules in the appropriate cellular compartment or 
extracellular space of any tissue of interest. For instance, the introduction 
of a moiety into a cell that leads to resistance of that cell to productive 
infection by viral pathogen has been entitled “intracellular immunization” 
by Baltimore et al. in 1988 (Baltimore, 1988) and this terminology was 
carried out by many authors to define the inhibition or inactivation of a 
function of a molecule by the ectopic intracellular expression of antibody 
binding domains that recognize the molecule (Biocca et al., 1995). 
The assembly of antibodies in ectopic cellular contexts, outside of their 
physiological environment may results by targeting of the antibodies to 
different intracellular compartments by the use of suitable localization 
signals (Biocca et al., 1990) (Biocca et al., 1995).  Many scientists have 
demonstrated that the antibodies can be functional and able to inhibit 
cellular function when expressed in different cellular context. 
One of the pioneers of intracellular antibody expression was John R. 
Carlson: in 1988 he tested the feasibility of inactivating a protein in vivo 
through the inducible, intracellular expression of an antibody into yeast 
cells. The protein target chosen was the cytoplasmic enzyme the alcohol 
dehydrogenase I (ADHI). He introduced in a yeast expression vector the 
heavy and the light chain cDNA encoding a neutralizing anti-ADHI 
monoclonal antibody under the control of a galactose-inducible promoter 
(Carlson & Weissman, 1988). This “yeast intracellular antibody” was 
stably synthesized and co precipitated as a complex with ADHI, indicating 
that the antibody was capable of assembly and able to bind the antigen. 
This antibody was also able to produce a limited degree of neutralization in 
vivo: when cells where plated under conditions that favor the growth of 
cells containing reduced levels of ADH, the intracellular binding of the 
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antibody with the ADHI confers some degree of allyl alcohol resistance 
upon cells in vivo.  
In 1990 Biocca et al., (Biocca et al., 1990) showed that by the use of 
suitable targeting sequences antibodies could be redirected to the desired 
intracellular compartments such as the nucleus. 
In 1991, Hilvert and coworkers (Bowdish et al., 1991) (Tang et al., 1991) 
have used intracellular antibodies to alter cell metabolism: they expressed a 
catalytic antibody, or abzyme, to endow a yeast cell with an enzymatic 
activity, catalyzing a step (normally catalyzed by the product of the yeast 
ARO7 gene) in aromatic amino acid synthesis. Using a high-copy 
expression plasmid in an aro7 mutant yeast cell, they were able to recover 
functional antibody from yeast and the function of the antibody was 
detected in vivo by complementing the aro7 defect in yeast mutant strain, 
allowing the cells to grow under selective conditions. 
In the same year Eugenio Benvenuto and coworkers engineered an 
immunoglobulin heavy-chain domain in a vector suitable for 
transformation of plants via Agrobacterium (Benvenuto et al., 1991). These 
studies represented the first alternative strategy to interfere with function of 
specific proteins involved in plant pathogenesis or development. 
Tavlodoraki et al. first reported the feasibility of plant immunoprotection 
against virus in 1993 (Tavladoraki et al., 1993). A constitutively expressed 
cytoplasmic scFv raised against the coat protein of the artichoke mottle 
crinkle virus (AMCV) was able to specifically shield transgenic plants 
from viral attack, reducing the infection incidence and causing a delay in 
symptoms development upon challenge with abnormally high titers of viral 
inocula. 
Many other authors have reported phenotypic alterations caused by 
intracellular antibody expression in mammalian system. 
In 1993, Marasco et al. described the intracellular expression and activity 
of a scFv antibody with a target signal to the endoplasmic reticulum, that 
recognize the envelope glycoprotein, gp120, of the HIV-1. They show that 
the antibody can be detected in the endoplasmic reticulum, co precipitates 
with the envelope protein, thereby inhibiting the processing of the envelope 
protein precursor and syncytia formation.  
In 1993, Biocca et al. report the expression of an anti ras proto-oncogene 
scFv fragment in the cytosol of Xenopus laevis oocytes: this single-chain 
Fv fragment was able to colocalize with the endogenous p21ras protein in 
the cytoplasmic face of the oocyte plasma membrane and to inhibit insulin-
induced meiotic maturation of the cell, a process known to be p21ras-
dependent.  
The efficacy of intracellular antibody expression has been reported in 
several applications to HIV viral proteins (Gargano et al., 1996) (Gargano 
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& Cattaneo, 1997a) (Mhashilkar et al., 1995) (Levy-Mintz et al., 1996) and 
also to oncogene products (Biocca et al., 1993) (Cochet et al., 1998). 
 
 
1.5.2 Assembly, Folding and Stability of Intracellular Antibodies 
It was very well demonstrated that antibodies for intracellular application 
could be directed to the relevant cellular compartments by modifying the 
antibody genes with N-terminus or C-terminus polypeptide extensions that 
encode classical intracellular-trafficking signals (Biocca et al., 1990) 
(Biocca & Cattaneo, 1995) (Marasco, 1995). 
Functional studies have demonstrated that scFv are able to fold and 
assemble correctly in several intracellular environments, but when 
antibodies are expressed in the cell cytoplasm, folding and stability 
problems often occur.  
One of these problems is that the cytosolic environment is not compatible 
with efficient disulphide bridge formation because of its reducing potential 
(Biocca et al., 1995). 
The reducing environment (Gilbert, 1990) inhibits the formation of the 
conserved intradomain disulphides in antibody variable regions (Biocca et 
al., 1995). The intradomain disulphide contributes about 4-5 kcal/mol to the 
stability of antibody domains (see Fig.1.8). Therefore, antibody fragments 
expressed in a reducing environment are strongly destabilized. 
Nevertheless, a number of cytoplasmically expressed antibody fragments 
are active (Cattaneo & Biocca, 1997) and tolerate the absence of the 
disulphide bond, depending on the particular primary sequence (Proba et 
al., 1997) (Proba et al., 1998). 
Therefore, the problem arises on how to access this subset of antibodies 
that tolerate the absence of the intrachain disulphide bond. This subset of 
antibodies is predicted to be more suitable for intracellular expression in 
the cell cytoplasm. 
Some natural antibodies lack disulphide bond in the heavy chain variable 
domain (Rudikoff & Pumphrey, 1986) (Proba et al., 1997). These 
observations have inspired attempts to engineer antibodies that do not rely 
on the formation of the disulphide bond for folding in the cell cytoplasm. 
The most common way to do this is the introduction of designed mutations 
that stabilize antibody fragments lacking one or both of the key cysteine 
residues involved in disulphide bond formation (Worn & Pluckthun, 1999). 
The improvement of the in vitro stability in a given scFv, by concentrating 
engineering efforts on the weak part of the molecule may improve in vivo 
performance of scFv fragments which can be used as stable frameworks, 
suitable as recipients in CDR grafting experiments. Although these kinds of 
improvements may lead to success in individual cases, it is not possible to 
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apply generally such rational approaches especially in functional genomics 
where large networks of interacting proteins are going to be studied. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1.8 The folding of antibody domains has a range between a minimum (m) and a 
maximum (M) value and is contributed by many residues in the frameworks (Proba et 
al., 1998). Different scFv fragments have different overall stabilities. Some scFv could 
tolerate the removal of intrachain disulphide bond and remain folded because they are in 
the upper range of folding stability (A), while those that are in the lower range will not 
(B). Moreover, there are some mutations that could stabilize the antibody fragments 
rendering them tolerant to the absence of the disulphide bonds (C*). 
 
 
 
Therefore, more general ways for selecting antibodies that perform 
efficiently in the different intracellular environments would be very useful. 
One other problem is that the folding of newly synthesized polypeptide 
chains depends also on the assistance provided by two kinds of pre-existing 
proteins located in the endoplasmic reticulum (ER), therefore, unavailable 
in the cytoplasm, that are molecular chaperones, such as prolyl isomerase, 
protein disulphide isomerase (PDI) and other folding catalysts (Ellis & 
Hartl, 1999) (Hartl et al., 1994) (Freedman, 1995) (see Fig.1.9). 
 
 
A 
B 
C* C* 
M 
m 
∆G=4.5 Kcal/mol 
 23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1.9 Protein Folding in E.coli. E.coli contains a number of helper proteins or 
“folding modulators”, that catalyze certain folding steps (folding catalysts) or prevent 
the aggregation of the unfolded proteins. 
 
 
Improper folding may prolong the interaction of the newly synthesized 
molecule with the folding enzymes and chaperones and can lead to 
degradation of the nonfunctional molecules. 
The reducing environment of the cell cytoplasm hinders the formation of 
the intrachain disulphide bond of the VH and VL domains (Biocca et al., 
1995) (Martineau et al., 1998) that is important for the stability of the 
folded protein. 
The disulphide bond between the b-strand and the f-strand in the 
immunoglobulin domain is highly conserved and has been maintained in all 
known germline genes of all antibodies (see Fig.1.10) 
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Fig. 1.10 Detailed overview of a model of a scFv fragment. In this model it 
is shown the disulphide-bonding between the two cysteine on the opposite b- and f-
strands of the heavy chain of a scFv fragment molecule (Proba et al., 1997). 
 
 
The reason for this conservation appears to be the relatively low stability of 
the domain, which requires additional stabilization by the disulphide. 
Only more stable domains can tolerate the removal of the disulphide bond 
causing a conformational change in which new hydrogen bonds are formed 
compensating the loss of free energy from the missing disulphide (Proba et 
al., 1997). 
Andreas Pluckthun and coworkers have extensively studied the tolerance of 
the disulphide loss of a natural C92Y mutation in the heavy chain of the 
anti-levan antibody ABPC48 (Proba et al., 1997) (Proba et al., 1998).  
They demonstrated that the restored disulphide in that particular antibody 
increased its stability by 4.5 kcal/mol, and also showed that the original 
variable domain is more stable then average, explaining why it tolerates the 
disulphide loss. In a subsequent work they generated stable and functional 
cysteine-free antibody single-chain fragments by DNA shuffling and phage 
display obtaining new proteins that exhibit thermodynamic stability similar 
to the natural ABPC48 scFv fragment.  
The approach taken in consideration by Pluckthun and many other authors 
would be the modification of the VH and VL sequences to replace the need 
for disulphide bonds to stabilize the scFv with either higher intrinsic 
stability (Worn & Pluckthun, 1998) or perhaps with differing intrachain 
stabilizing factors, such as metal binding residues. Such rational 
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approaches may lead to success in individual cases but generating generic 
frameworks may be difficult.  
For this reason we have exploited a more general strategy in order to apply 
selection to the derivation of intracellular antigen-binding antibodies or 
fragments, allowing the isolation based on binding efficacy in vivo rather 
than a designer approach. 
Our hypothesis is that the natural repertoire contains many stable 
antibodies that could be rescued with an appropriate method without 
making any molecular evolution strategy. 
 
 
 
1.4.3 Potentials and Limitations of Intrabody Technology on a 
Genome-Wide Scale 
In a recent review of Rogert Brent (Brent, 2000), there is an exhaustive 
analysis of which ad hoc experimental methods can be applied to 
functional genomics. 
The ideal genomic experimental techniques should be: 
• Cheap 
• Accessible 
• Nonproprietary 
• Undertakeable  
• Seeking answers to specific questions 
• Generic: they should not depend on special properties 
• Simple: such techniques must not require great skill in order to 
systematize them 
At present there are several techniques that should be useful to generate 
affinity reagents against all encoded proteins, encoded by a given genome 
to knocking-out their function, and they include: 
a) Antisense nucleic acids and dsRNA 
b) Nucleic acid aptamers 
c) Peptide aptamers 
d) Intracellular antibodies 
As described before, the first three tools suffer from drawbacks and 
limitations related to intrinsic technical problems or to experimental design. 
The use of intracellular antibodies can have great potential as an 
alternative/complementary strategy in defined situations, and the large 
number of careful studies showing the efficiency of this techniques, 
demonstrate the feasibility of this approach not only as a powerful 
experimental strategy in gene therapy (Marasco, 1995) and plant 
technology (Benvenuto & Tavladoraki, 1995), as previously suggested, but 
also in functional genomic as we now propose (Visintin et al., 1999). 
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The potential of intrabodies may be realized in the near future in functional 
genomics systematic screening programs and may play a central role either 
in conjunction with, or in place of, the other knock-out tools described in 
this chapter.  
Notwithstanding the successes, the work performed so far has indicated 
quite clearly which improvement can be achieved and are required. They 
include above all, improvement in folding stability and cellular half-life, 
tolerance of disulphide bond absence, affinity and refinements of 
intracellular targeting. 
Further improvements can be achieved by increasing selection stringency, 
using the selected frameworks to generate more active antibodies or 
engineering a new selection strategy for generating functional, soluble and 
stable antibody for intracellular expression. 
Recent advances were also reported in antibody expression in E.coli and in 
the design of new selection schemes in mammalian cells, which show the 
working directions to achieve substantial improvements in the properties of 
intracellular expression of antibody domains. 
In principle, the selection of good intrabodies may be performed on the 
basis of rescued phenotype and/or on the basis of binding under condition 
of intracellular expression.  
Two studies showed the proof of principle of the formed strategy. 
In 1997 Gargano et al., (Gargano & Cattaneo, 1997b) explored the 
possibility to rescue a neutralizing anti-viral antibody fragment from an 
intracellularly expressed anti-reverse transcriptase polyclonal repertoire. By 
exposing the cell population to the selective pressure of a cytotoxic 
retrovirus, they were able to show a strong inhibition of RT activity in 
those clones in which the expression of a specific anti-reverse transcriptase 
neutralizing antibody fragment was found. The results demonstrated that 
only the cells expressing the neutralizing antibody fragment can be 
efficiently rescued using as a unique selection the expression of antibody 
fragment. 
In 1998 Martineau and coworkers, (Martineau et al., 1998) demonstrated 
that folded and functional antibody fragments can be isolated in the 
bacteria cytoplasm after successive rounds of mutation and selection on the 
basis of the obtained phenotype. They subjected the gene encoded the 
“activating” anti-β-galactosidase scFv fragments to random mutation in 
vitro by error-prone PCR, and co-expressed the mutant β-galactosidase and 
mutant antibody fragments in lac- bacteria in order to convert the cells to 
lac+.  
After plating on limiting lactose, they were able to select for antibody 
mutants with improved expression properties. 
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Selection strategy purely based on intracellular antigen binding regardless 
of the particular phenotype generated, are however more general. 
To this aim, we have exploited the yeast two-hybrid system to monitor and 
to select intracellular antigen-antibody interactions via reporter gene 
activation (Visintin et al., 1999).  
The main procedure of this new selection strategy all based on in vivo 
binding is outlined in Fig. 1.11 
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The improvements yielded by this new technology are remarkable, because 
they fill the limitations shown so far.  
The next chapter will describe all the steps taken in order to achieve the 
developing of this technology and the application of this method in a 
specific in vivo selection using a protein that need intracellular antibodies 
for both research and applicative purposes. 
The potential of intrabodies in functional genomics will be described 
during the discussion in the next chapters. 
 
29 
Chapter Two: Materials and Methods 
 
 
 
2.1 General Protocols for the Antibody-Antigen Two-Hybrid 
System 
 
 
2.1.1 Yeast strain 
The interaction system that we have used requires the yeast strain L40 
(Hollenberg et al., 1995) which contains lexA operator-responsive 
reporters chromosomally integrated; the genotype of L40 is: 
Mata his3∆200 trp1-901 leu2-3,112 ade2 LYS2::(lexAop)4-HIS3 
URA3::(lexAop)8-lacZ GAL4 
Minimal HIS3 and GAL1 promoters fused to multimerized lexA binding 
sites drive the expression of the HIS3 and lacZ coding sequences, 
respectively. The expression of HIS3 gives a growth selection for 
interaction while the expression of lacZ, which encodes the enzyme β-
galactosidase, can be monitored using a colorimetric assay based on the 
activity of β-galactosidase: the lacZ+ yeasts form blue colonies in the 
presence of the chromogenic substrate 5-bromo-4-chloro-3-indolyl-β−D 
galactoside (X-gal). 
This strain is deficient for TRP and LEU (auxotrophic phenotype) and 
cannot grow on minimal medium lacking those nutrients unless functional 
TRP1 and LEU2 genes are introduced. Moreover, this strain carries the 
ade2 mutation, which confers a red color (due to a red pigment 
accumulation) on medium containing limiting amounts of adenine that 
turns darker as the colony age. 
 
 
 
2.1.2 Plasmids 
There are several vectors for use with the two-hybrid system and in general 
they have a number of features in common. Not all the vectors in use can 
be utilized for this purpose, in particular the choice of terminal fusion for 
the scFv fragment can be crucial because of the steric hindrance of the 
molecule.  
The two-hybrid vectors described here are plasmids that contain replicators 
and genetic markers that allow their selection and maintenance both in 
S.cerevisiae and in E.coli. The drug resistance markers and replicators that 
allow selection and maintenance in E.coli are standard (bla and ori 
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sequences respectively), whereas those that allow use in yeast are more 
specialized.  
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Fig. 2.1 pBTM116 (Bartel et 
al., 1993) 5-kb DNA-binding 
domain vector; is used to 
generate fusions of the target 
antigen with the complete lexA 
coding sequence, with 
downstream polylinker for 
cloning genes of interest to 
generate in-frame protein 
fusions to lexA, expressed from 
the yeast ADH1 promoter. It 
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selectable marker for yeast and 
the yeast 2µ origin of 
replication. 
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Fig. 2.2 pVP16* (Hollenberg et al., 1995) 
7.5-kb activation domain vector, is used to 
generate fusions of a known scFv or a scFv 
library with the VP16 activation domain, 
with upstream polylinker for cloning genes of 
interest to generate in-frame fusions to VP16, 
expressed from the yeast ADH1 promoter. It 
contains LEU2 gene, a nutritional marker that 
must be used in conjunction with special host 
strains, as L40, that carry the appropriate 
complementable mutions. It contains also two 
SV40 large antigen nuclear localization 
sequences (NLS) fused to the VP16 acidic 
activation domain and the yeast 2µ origin of 
replication. ATG indicates the initial of 
transcription of the polylinker of the 
activation domain VP16 vector. The pVP16* 
polylinker was engineered for suitable 
cloning from library, which has SfiI-NotI 
cloning sites for scFv fragments as for 
example, Vaughan 96 (Vaughan et al., 1996) 
and Sheets 98 (Sheets et al., 1998). 
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Both plasmids contain ADH1 transcription terminators, downstream from 
the promoter and the cloning-fusion sites. 
 
 
 
2.1.3 Preparation of Media and Reagents 
Yeast strains, which employ auxotrophic mutations as markers, are grown 
on nutrient-rich media at 30°C to minimize selections for revertants.  
Strains to be preserved are grown to logarithmic phase on YPD plates; the 
yeast is then scraped up with sterile inoculation loop and suspended in a 
15-30% (v/v) glycerol-YPD medium; yeast can be stored now indefinitely 
at -70°C (the vials should be vortex briefly before freezing at -70°C to 
avoid cells settling to the bottom of the tube). 
When needed, the yeast strain can be revived by transferring a small 
portion of the frozen sample onto YPD plates (yeast L40 colonies should 
appear slightly pink onto YPD plates and grow to >2 mm in diameter); 
yeast can be also stored at 4°C on YPD plates for up to 2 months. To verify 
the phenotype of the yeast strain provided, the streaking of few colonies 
from the working stock onto separate YC plates is performed (see table); 
phenotype will appear after 3-4 days of incubation at 30°C. 
 
 
 
YPD medium  
10 g yeast extract (Difco # 0127-17)  
20 g peptone (Difco # 0118-17 )      
20 g bacto-agar (Difco # 0140-01)       
2% glucose  
Add H2O to 950 ml. Adjust pH to 5.8 then adjust to 1 liter. Autoclave 
121°C for 15 min. 
 
YPA medium 
10 g yeast extract 
20 g peptone 
20g bacto-agar 
0.1g Adenine hemisulfate salt 
Add H2O to 950 ml. Adjust pH to 5.8 then adjust to 1 liter. Autoclave 
121°C for 15 min. 
 
 
32 
YC medium 
 
1. YNB w/o aa & (NH4)2SO4: 
1.2 g yeast nitrogen base, w/o amino acids and ammonium sulfate (Difco # 
0335-15-9) 
20 g bacto-agar 
Add H2O to 800 ml. Autoclave  121°C for 15 min. 
 
 
2. Salts: 
5.4g NaOH 
10g succinic acid (Sigma # S-7501) 
5g ammonium sulfate (Sigma # A-
3920) 
 
3. Glucose: 
22g D-glucose 
Dissolve in 16 ml H2O 
Add H2O to 100 ml and dissolve all components one by one. Add glucose 
and H2O to make a final volume of 150 ml. 
 
 
4. amino acids MIX:  
5.8 g NaOH 
1 g Adenine hemisulfate salts 
1 g L-Arginine HCl (Sigma # A-5131) 
1 g L-Cysteine (Sigma #  C-8277) 
1 g L-Threonine (Sigma #  T-8625)  
0.5 g L-Aspartic acid (Sigma # A-4534) 
0.5 g L-Isoleucine (Sigma # I-7383) 
0.5 g L-Methionine (Sigma #  M-9625) 
0.5 g L-Phenylalanine (Sigma # P-5030) 
0.5 g L-Proline (Sigma # P-4655) 
0.5 g L-Serine (Sigma # S-5511) 
 
Dissolve in 80 ml H2O 
 
 
5. L-Tyrosine: 
0.5 g L-Tyrosine (Sigma # T-3754) 
0.2 g NaOH 
Dissolve in 10 ml by heating 
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6. Omitted aminoacid solutions: 
L-Histidine (Sigma # H-9511): 
• 5 g/l H2O 
Uracil (Sigma # U-0750) : 
• 10 g/l H2O (+2 pellets NaOH) 
L-Leucine (Sigma # L-1512): 
• 10 g/l H2O 
L-Lysine HCl (Sigma # L-1262): 
• 10 g/l H2O 
L-Tryptophan (Sigma # T-0254): 
• 10g/lH2O 
 
Add to aa MIX (4.) the L-Tyrosine solution (5.) and H2O to make a final 
volume of 100 ml. Filter –sterilize, aliquot and store at -20°C for up to 1 
year. 
Filter-sterilize and aliquot individually omitted amino acids (aa) solutions 
(H, W, L, K, U) and store at -20°C for up to 1 year. 
Before preparing YC plates or media by mixing appropriate solutions, 
media must be adjusted to pH 5.8 and sterilized by filtering salts + aa final 
mix. All the components must be mixed as suggested in Table 2.1: 
 
 
 
 YNB w/o aa 
& 
(NH4)2SO4 
 
Salts aaMIX W H U L K H2O 
-W 800 150 10  10 10 10 10  
-L 800 150 10 10 10 10  10  
-WL 800 150 10  10 10  10 10 
-UW 800 150 10  10  10 10 10 
-WHUK 800 150 10    10  30 
-WHULK 800 150 10      40 
 
Table 2.1 Note: All the suggested volumes are expressed in ml. 
 
 
 
2.1.4 Construction and characterization of the “bait“ 
The first step in a two-hybrid assay is the construction of the „bait“. A 
series of control experiments must be performed to establish whether the 
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fusion protein is suitable as such or whether it must be modified; the 
verifications of well-behaved bait are:  
 
a) testing for activity  
b) testing for expression 
c) testing for toxicity 
 
a) activity 
A well-behaved bait should not transactivate in a non-specific way the 
reporter genes in the L40 strain and should not interact with either the 
nuclear localization signals or with the VP16 activation domain. Therefore, 
the L40 strain transformed with the bait alone or together with pVP16* 
plasmid should not grow in the absence of histidine and should not contain 
any detectable β−galactosidase activity. Note: the bait must be modified by 
using a particular domain or a deletion mutant of the same protein in frame 
to lexA if it does not fulfill all the proposed features. 
Test the extent of non specific activation of the reporter construct by the 
bait plasmid with the following protocol: 
1) transform the bait plasmid into L40 strain using the small-scale yeast 
transformation protocol 
2) select for transformants on appropriate YC plates as described in Table 
2.2 
3) assay the bait construct for activation of HIS3 reporter gene as described 
in Table 2.2 and for activation of the lacZ reporter gene using the 
β−galactosidase colony-filter assay as described below 
 
LiAc transformation (small-scale) 
This protocol is a modification of published methods (Gietz et al., 1992), 
(Hill et al., 1991), (Schiestl & Gietz, 1989) made by Clontech laboratories. 
The expected transformation efficiency is 10
3
-10
4 
/ µg plasmid DNA. 
 
Materials 
• 10X LiAc buffer: 1M LiAc, pH 7.5 adjusted with diluted glacial acetic 
acid filter-sterilized (lithium acetate dehydrate –Sigma # L-6883)  
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• 50% (w/v) filter-sterilized PEG 4000: polyethylene glycol, avg. mol. 
wt.=3350-Sigma # P-3640. (Solution must be kept in a tightly sealed 
glass bottle to avoid evaporation) 
• 10X TE buffer: 100mM Tris, 10mM EDTA, pH7.5, filter-sterilized 
• 100% DMSO: dimethyl sulfoxide 
• 10 mg/ml denatured herring testes carrier DNA (Clontech # K1606) 
Procedure 
Day 1: Inoculate few colonies of L40 in 50 ml of YPD and incubate for 16-
18 hr with shaking at 250 rpm at 30°C to place the culture at mid log phase 
the next day (OD600 > 1.5). Note. Use only glass flasks carefully washed 
with ultra pure, pyrogen-free water and sterilized by autoclaving 15 min at 
121°C. 
Day 2: 
 1) Dilute the overnight culture to OD600 0.2-0.3 in 300 ml of YPD 
prewarmed to 30°C. Grow at 30°C for 3 hours with shaking (230 rpm) 
2) Pellet the cells by centrifugation (1000 X g for 5 min) at room 
temperature, discard the supernatant and resuspend the pellet in 50 ml of 
H2O. 
3) Centrifuge the cells again as in 2), decant the supernatant 
4) Resuspend the pellet in 1.5 ml of freshly prepared 1X TE/LiAc (10mM 
TE, 0.1M LiAc) 
5) Prepare in a tube a mixture of:  
 0.1 µg lexA-Ag vector construct 
 0.1 µg scFv-VP16 vector construct (if you need to test specific antigen-
antibody partners) 
 0.1 mg herring testes carrier DNA 
6) Add 0.6 ml of a sterile PEG/LiAc (0.1 M LiAc, 10mM TE, PEG 4000 
40%) to the tube and vortex to mix 
7) Incubate 30 minutes at 30°C with shaking (230 rpm) 
8) Add 70 µl of DMSO, mix gently by inversion and heat shock for 15 min 
in a 42°C water bath. 
9) Chill cells on ice 
10) Pellet cells by centrifugation (20 sec at maximum speed) 
11) Remove supernatant and resuspend cell in 0.5 ml of sterile 1X TE; 
spread 100 µl for single transformation or 250 µl for a co-
transformation on each 100 mm plate. 
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LiAc transformation (maxi-scale) 
The following transformation protocol is a modification of published 
methods made by Invitrogen laboratories (Gietz et al., 1992), (Hill et al., 
1991), (Schiestl & Gietz, 1989). This protocol should be applicable for 
cDNA library transformation when a higher efficiency of transformation (≅ 
10
6
/µg DNA) is needed.  
Materials 
 500 µg scFv/VP16* DNA   
 150 ml YC-UW  
 2 l YPAD 
 1 l YPA 
 1.5 l YC-UWL + 10 YC-UWL plates (100mm) 
 1.5 l YC-WHULK + 100 YC-WHULK plates (100mm) 
 100 ml 10X TE 
 20 ml 10X LiAc 
 1 ml of 10 mg/ml denatured salmon sperm 
 150 ml 50% PEG 4000 
 20 ml DMSO 
Procedure 
1. Day1: grow L40 yeast containing bait plasmid in YC-UW O/N 
2. Day2: inoculate 100 ml of YC-WU with an aliquot of the overnight 
culture in order to find a dilution that places the 100 ml culture to 
logarithmic phase the next day 
3. Day3: transfer enough overnight culture in 1 l of prewarmed to 30°C 
YPAD to produce an OD600 = 0.3 
4. Grow at 30°C for 3 hours 
5. Centrifuge the cells at 1500 X g for 5 min at room temperature 
6. Wash pellet in 500 ml of 1X TE then centrifuge again the cells at 
1500 X g for 5 min at room temperature 
7. Resuspend pellet in 20 ml 1X LiAc, 0.5X TE and transfer to a new 
flask 
8. Add 500 µg DNA library and 1 ml denatured salmon sperm 
9. Add 140 ml of 1X LiAc, 40% PEG 3350, 1X TE; mix and incubate 
for 30 min at 30ºC with gently shaking 
10. Add 17.6 ml of DMSO; swirl to mix 
11. Heat shock for 10 minutes at 42ºC in a water bath swirl occasionally 
to mix 
12. Rapidly cool at room temperature cells in a water bath diluting with 
400 ml YPA 
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13. Pellet cells by centrifugation and wash with 500 ml YPA 
14. After centrifugation resuspend pellet in 1 l of prewarmed YPAD 
15. Incubate at for 1 hour at 30°C with gently shaking 
16. Pellet cells from 1 ml: resuspend in 1 ml YC-UWL; spread 100 µl of 
a 1:1000, 1:100, 1: 10 dilutions for transformation efficiency 
controls 
17. Pellet cells from the remaining culture 
18. Wash pellet with 500 ml YC-UWL 
19. Resuspend in 1l of prewarmed YC-UWL and incubate O/N at 30°C 
with gently shaking 
20. Day4: pellet cells and wash twice with 500 ml of YC-WHULK 
21. Resuspend final pellet in 10 ml of YC-WHULK 
22. Spread dilutions of the total on YC-UWL plates to compare to the 
number of primary transformants 
23. Spread the remaining transformation suspension on YC-WHULK 
plate 
 
 
β−galactosidase filter assay 
(Breeden & Nasmyth, 1985)  
Materials 
 Nitrocellulose filter circles (Scheicher and Schuell BA85) 
 Buffer Z (60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1mM 
MgSO4, pH 7.0) 
 50 mg/ml 5-bromo-4-chloro-3-indolyl−β−D-galactoside 
 Whatman filter circles 
 Liquid nitrogen 
Procedure 
1) Patch yeast colonies to a nitrocellulose filter circle 
2) Lift filter and place colony side up on a pre-cooled aluminum boat 
floating upon a sea of liquid nitrogen 
3) After 20 seconds, immerse boat and filter for 5 seconds 
4) Allow the filter to come to room temperature and place on top of 
Whatman filter circle that had been prewet in 3 ml of Z buffer 
containing 30 µl of X-gal  
5) Incubate the filter for up to 5 hours. Blue coloration is indicative of 
β−gal activity. 
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Transformation controls for well-behaved „bait“ 
 
„bait“ „prey“ YC selection 
medium 
HIS3 
phenotype 
lacZ 
phenotype 
Ag/BTM116  -W / white 
Ag/BTM116  -WHUK /  
Ag/BTM116 VP16* -WL  white 
Ag/BTM116 VP16* -WHULK /  
 
Table 2.2 
 
 
b) expression 
• Preparation of Crude Yeast Lysate for SDS-PAGE analysis 
 
To verify that the bait fusion protein is properly synthesized, an SDS-
PAGE and immunoblot analysis on crude yeast lysate must be performed. 
Materials 
 master plate with bait-containing positive and control yeasts 
 antibody to lexA (Invitrogen) or monoclonal/polyclonal to fusion 
protein 
 Laemmli sample buffer 2x 
Procedure 
Day 1: 
Incubate overnight at 30°C a 5-ml culture of the bait being tested and 
relative controls in the appropriate YC medium. 
Day 2: 
1) From each overnight culture start a new 5-ml culture at OD600= 0.15. 
Incubate at 30°C until the culture has reached OD600= 0.5-0.7. 
2) Remove 1.5 ml to a tube and centrifuge cells 3 min at maximum speed 
3) Remove the supernatant and working rapidly resuspend in 50 µl of 2x 
Laemmli sample buffer. 
4) Vortex and place immediately the tube on dry ice.  
5) Boil 5 min and centrifuge 1 min at maximum speed the sample before 
loading it on SDS-PAGE. 
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c) toxicity 
A high level expression of the fusion protein could be toxic to the reporter 
strain and this could lead the transformant cells to be unable to grow. To 
alleviate this detrimental effect the truncation of the toxic protein or a 
conditional promoter on hybrid plasmid could be used. 
 
 
 
2.1.5 Construction and characterization of „prey“ 
 
The second step in a two-hybrid assay is the construction of the „prey“. In 
our case, the prey is a single scFv fused in frame with VP16 or a scFv 
library. A series of control experiments must be performed also with prey 
constructs in order to verify the expression level of the protein and its 
specificity (see Table 2.3).  
In order to evaluate the specificity of the scFv fusion protein, all scFv-
VP16 fragments tested should interact specifically with their relative bait 
but not with a non-relevant antigen (human lamin) (Bartel et al., 1993) 
(Hollenberg et al., 1995). 
 
 
2.1.5.1 Transformation controls for a well-behaved „prey“ 
 
„bait“ „prey“ YC selection 
medium 
HIS3 
phenotype 
lacZ 
phenotype 
Lamin/BTM116  -W  white 
Lamin/BTM116  -WHUK /  
 scFv/VP16 -L  white 
 scFv/VP16 -WHUK /  
Lamin/BTM116 scFv/VP16 -WL  white 
Lamin/BTM116 scFv/VP16 -WHULK /  
Ag/BTM116 scFv/VP16 -WHULK + blue 
 
Table 2.3 
 
 
To see the expression level of the scFv fusion protein a western blot must 
be performed using an anti VP16 polyclonal antibody (Santa Cruz 
Biotechnology). Note: the high background level produced by this 
polyclonal antibody can affect the resolution of the experiment. Therefore 
to have better results the use of the myc tag present at the 3’end of the scFv 
40 
does not interfere in fusion constructs. To detect in western blot these 
tagged proteins the monoclonal antibody 9E10 (Evan et al., 1985) should 
be used. 
 
 
2.1.5.2 Plasmid segregation to remove bait plasmid 
Procedure 
1) Inoculate lacZ+ His+ transformants in 5 ml of YC-L and grow at 30°C 
with shaking for 2 days 
2) Plate 100 µl of a 1:1000 dilution of the 2 days cultures onto YC-L plate 
and incubate for 2 days at 30°C 
3) Replica plate the colonies growing on YC-L first on YC-WL and then to 
YC-L; incubate 2 days at 30°C 
4) Isolation of colonies that grow on YC-L but not on YC-WL 
 
 
2.1.5.3 Plasmid isolation from yeast 
The rapid procedure for the isolation of plasmid DNA from yeast is based 
on the method adapted from QIAprep Spin Miniprep Kit protocol by 
Michael Jones, Chugai Institute for Molecular Medicine, Ibaraki, Japan. 
Plasmid DNA isolated from yeast is contaminated by yeast genomic DNA: 
the procedure described below has been successfully used for 
transformation of E.coli, for restriction analysis, PCR screening and 
sequencing. 
 
Procedure 
1) Inoculate single, well isolated yeast transformant colonies into 5 ml of 
appropriate selective media at 30°C with shaking at 250 rpm until the 
culture is saturated (16-24 hours) 
2) Spin down the culture by centrifuging at 5000 x g and resuspend cells in 
250 µl of Buffer 1 containing 0.1 mg/ml RNase A; transfer the cell 
suspension in a 1.5 ml microfuge tube 
3) Add 0.3 g of acid-washed glass beads and vortex for 5 min at room 
temperature 
4) Spin at maximum speed for 5 min and transfer the supernatant to a new 
1.5 ml microfuge tube 
5) Add 250 µl lysis buffer P2 to the supernatant and invert gently 4-6 times 
to mix. Incubate at room temperature for 5 min. 
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6) Add 350 µl neutralization buffer N3 to the tube and invert immediately 
4-6 times the tube 
7) Centrifuge at maximum speed for 10 min  
8) Transfer the cleared lysate to QIAprep spin column placed in a 2 ml 
collection tube by pipetting 
9) Centrifuge for 1 min at maximum speed; discard the flow-through 
10) Wash QIAprep spin column by adding 0.75 ml of Buffer PE and 
centrifuging for 1 min 
11) Discard the flow-through and centrifuge for an additional 1 min to 
remove residual ethanol from wash buffer 
12) Place QIAprep spin column in a clean 1.5 ml microfuge tube.  
13) Add 25 µl of H2O to the center of each QIAprep spin column; let 
stand for 1 min, and centrifuge for 1 min at maximum speed 
 
 
2.1.6 Verification of a positive Ag-scFv two-hybrid interaction 
The general use of yeast cells to detect antigen-scFv interaction was 
assessed with scFv derived either from monoclonal antibodies or from 
phage display antibody libraries, and some of which had been shown to 
have biological activity when assayed in vivo. The final validation for a 
positive interaction was assessed testing the co-transformed yeast colonies 
for His and lacZ gene activation.  
 
 
 
2.2 Experimental Protocols to Monitor Intracellular Antigen-
Antibody Interactions Using The Two-Hybrid System 
 
 
2.2.1 Vectors: Construction was performed according to standard 
molecular biology techniques (Sambrook et al., 1990). 
 
To construct pLexA-AMCVp41, the p41 gene was amplified by RT-PCR 
from artichoke mottle crinkle virus (AMCV) RNA by using primers:  
5' - GCCCGAATTCATGGCAATGGTAAAGAGAAATAAT- 3' (sense) 
5'-TTACAGGATCCCTAAATTAAAGAGACATCGTTGT-3' 
(antisense). 
Total RNA from AMCV was isolated using 2X extraction buffer in DEPC 
treated H2O: 
• 20mM Tris-HCl 
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• 2% SDS 
• 20mM EDTA  
• pH > 8.5 
 
1) Add an equal volume of 2X extraction buffer to the virus suspension 
2) Check the pH. It should be> 8.5. If not, add some NaOH diluted in 
bidistilled H2O (DEPC treated) 
3) Keep on ice for 10 min. Check SDS precipitation, in case transfer the 
tube at RT 
4) Extract RNA with phenol chloroform V/V (phenol should be 
equilibrated in 0.1 M TRIS pH8 and the final pH should be > 7.5) 
5) Precipitate RNA with 1/10 volume 3M Na Acetate and 2.5 volumes 
ethanol precipitation. 
6) Dry the pellet (shortly in SpeedVac). Resuspend in the buffer 
required 
 
cDNA was prepared using SuperScript II RNase H- Reverse Transcriptase 
(Gibco BRL) with random hexamers according to the instructions of the 
manufacturer: 
 
 
1) In an eppendorf tube add the following in order: 
• 1 µl random primers (100 ng/µl) 
• 8 µl of total RNA (1-5 µg) 
• 3 µl sterile distilled water 
2) Heat to 70°C for 10 min and chill quickly on ice 
3) Centrifuge briefly in eppendorf to collect contents to bottom of the 
tube 
4) Add: 
• 4 µl 5X first strand buffer (250mM Tris-HCl pH8.3 at room 
temperature) 
• 2 µl 100mM DTT 
• 1 µl 10mM dNTP mix (10mM of each of dATP, dGTP, dCTP 
and dTTP at pH 7) 
5) Add 1 µl (200 units) SuperScript II RNase H- Reverse Transcriptase 
(Gibco BRL) and mix gently by pipetting up and down 
6) Incubate 25°C for 10  
7) Incubate 42°C for 50 min 
8) Inactivate at 70°C for 15 min 
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PCR was carried out using 1/10 of the obtained product with PFU 
polymerase in a PTC100 thermal cycler (MJ Research), for 30 cycles as 
follows: 
 
 
94°C –1 min   
60°C –1 min   30 cycles 
72°C -1min 30 sec  
72°C-10 min 
4°C-24h 
 
Aliquots of PCR reactions were checked on 1.5% agarose gel. PCR 
products were gel-purified using the QiaQuick Gel Extraction Kit 
(Qiagen). 
Purified PCR products were digested with EcoRI-BamHI, and inserted 
into EcoRI-BamHI sites of pBTM116.  
 
To construct pLexA-K-Ras, the K-Ras B gene was amplified by PCR from 
pGem3Z-k-ras (gently provided by Prof. Giancarlo Vecchio, Universita' 
degli Studi di Napoli FedericoII) by using primers: 
5'GATCGGATCCGTATGACTGAATATAAACTTGTGGTAGTTGGAG
CTGGT- 3' (sense)  
5' -GATCCTGCAGTTACATAATTACACACTTTG- 3' (antisense). 
PCR products were digested with BamHI-PstI, and inserted into BamHI-
PstI sites of pBTM116. 
 
To construct pLexA-Syk, the Syk gene was amplified by PCR from Syk 
cDNA by using primers: 
5'-GCCCGAATTCATGGCGGGAAGTGCTGTGGACAGCGCC-3' 
(sense)   
5'-TTACAGGATCCTTAGTTAACCACGTCGTAGTAGTAATTGCG-3' 
(antisense). 
PCR product were digested with EcoRI-BamHI, and inserted into EcoRI-
BamHI sites of pBTM116. 
 
To construct pLexA-β-gal, the β-gal gene was amplified by PCR from 
pBluescriptβ-gal7 by using primers: 
5' -GAATTCCCGGGGATCCGTATGACCATGATTACG- 3' (sense) 
5'-GATCCGTCGACCTGCAGGCTATTTTTGACACCAGAC-3' 
(antisense). 
PCR product were digested with BamHI-PstI, and inserted into BamHI-PstI 
sites of pBTM116. 
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To construct pLexA-HIV-1IN33, the HIV-1IN33 gene was amplified by 
PCR from pRP1012 by using primers: 
 5'-GCTAGCCCGGGGATCCCAATGTTTCTAGATGGAATCGAT-
3'(sense) 
5'-AGCCCCGGGATCCTGCAGCTAATCCTCATCCTGTCTACT-3' 
(antisense). 
PCR products were digested with BamHI-PstI, and inserted into BamHI-
PstI sites of pBTM116. 
 
To construct pscFvF8-VP16*, the scFvF8 gene was amplified by PCR 
from pGEMscFv(F8) by using primers: 
5'AATGGACTATGGCCCAGCCGGCCAATGCAGGTGCAGCTGCAG
GAG-3' (sense) 
5'-TCACCTGATAGCGGCCGCATTCAGATCCTCTTCTGAGAT-3' 
(antisense). 
PCR products were digested with SfiI-NotI, and inserted into SfiI-NotI 
sites of pVP16*. 
 
pscFvY13-VP16* was constructed by subcloning SfiI-NotI fragments from 
pHENY13 into SfI-NotI cut pVP16*. 
 
pscFvV6C11-VP16*, pscFvG6G2-VP16* and pscFvG4G11-VP16* were 
constructed by subcloning NcoI-NotI fragments from pscFvexpV6C11, 
pscFvexpG6G2 and pscFvexpG4G11 respectively into NcoI-NotI cut 
pCANTAB6 and subcloning again SfiI-NotI fragments from 
pCANTAB6scFvV6C11, pCANTAB6scFvG6G2 and 
pCANTAB6scFvG4G11 respectively into SfiI-NotI cut VP16*. 
 
To construct pscFvIN33-VP16*, the scFvIN33 was amplified by PCR 
from pNLVP16 by using primers: 
5'-
AAAAAGAGAAAAGTGGCCCAGCCGGCCATGGGAATGGACATCC 
AGATGACA-3' (sense) 
5'GGCGGAGCTCGAGGCGGCCGCTGAGGAGACGGTGAGGCT3' 
(antisense), digested SfiI-NotI, and inserted into SfiI-NotI sites of VP16*. 
 
To construct the non-relevant scFv/VP16* library for the Model Selection, 
DNA phagemids from a phage antibody library was extracted (Qiagen 
midiprep kit) and scFv fragment DNA was subcloned into SfiI/NotI sites of 
pVP16*. Naive pscFv/VP16* library had been added into pscFvF8/VP16* 
DNA at the dilution of 500.000:1.  
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The various plasmids were transformed into L40 yeast strain using small -
scale lithium acetate transformation. 
Positive clones were selected using auxotrophic markers for both plasmids 
and for lysine and histidine prototrophy (Hollenberg et al., 1995). 
Histidine-positive colonies and controls were lysed in liquid nitrogen and 
assayed for β-galactosidase activity on filters as described before. 
All clones were sequenced to confirm in-frame fusion of the inserts with 
the LexA binding domain or the VP16 in the vectors. 
 
 
2.2.2 Fingerprinting PCR bands 
Each individual V region of scFv gives an own “fingerprint”. 
Fingerprinting carried out on V genes will give a number of discrete bands. 
They can be carried out on V regions amplified from cDNA from 
individual clones: a good library contains different fingerprinting each 
clone. 
Pick one clone with a toothpick and dissolve it in 100 µl ddH2O. Use 1 µl 
in PCR reaction mix: 
 
DNA clone  1 
PCR buffer  2 
dNTP 2mM  2 
Taq   1 
VHmixBACK 1  (Sblattero & Bradbury, 1998) 
VKmixFOR  1   
ddH2O  12 
94°C –1 min   
55°C –1 min   30 cycles 
72°C –1 min 30 sec  
72°C-10 min 
4°C-24h 
 
 
 
Check PCR amplifications on a 1.5% agarose gel, using 3 µl each PCR 
reaction mix. After verification, use the other 17 µl of reaction mix for 
digestion: 
 
DNAmix   17 
BstNI (20U/µl)  0.2 
NEB buffer 2  4 
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BSA    0.4 
ddH2O   18.4 
 
Put to incubate at 60°C for 2 hours. Add 5 µl 6X gel loading buffer to each 
tube and load on 4% Metaphor/Nusieve TBE gel. Run 60V-120 min. 
 
 
2.2.3 Western blot and analysis of intrachain disulfide bonds 
Yeast protein extracts were prepared as described before; 20µl of sample 
were subjected to SDS-PAGE (12% acrylamide gels), in the presence or 
absence of β-mercaptoethanol, and gels were blotted onto nitrocellulose 
membranes (Schleicher & Schuell). For immunodetection, the monoclonal 
antibody anti-myc antibody 9E10 (Evan et al., 1985) (1:2000 in 2% MPBS) 
was used, followed by incubation with a polyclonal anti-mouse-peroxidase 
conjugate (DAKO) (1:2000 in 2% MPBS). 
 
 
 
 
2.3 Construction of tau deletion mutants for the ectopic 
expression in COS cells 
 
 
The expression vector pSG5 was used for all the constructs, directing the 
expression of the corresponding fragments of tau. The numbering of tau 
fragments is according to the longest human tau isoform tau40. Plasmids 
encoding tau fragments were generated by PCR using tau40/pSG5  (Fasulo 
et al., 1996) (Fasulo et al., 2000) as template. All the clones were 
sequenced using the Epicentre Sequitherm Excel II kit (Alsbyte, Mill 
Valley, CA) and analyzed on a Li-Cor 4000L automatic sequencer 
(Lincoln, NE). 
All the primers contained EcoRI (5’) and BamHI (3’) sites for the insertion 
into EcoRI-BamHI cutted pSG5. 
 
 
Primers: 
 
Sense (for tau 151-274, -305, -336, -368, -402, -412, -422, -432, -441) 
 
5’GCCCGAATTCATGATCGCCACACCGCGGGGAGCA 3’ 
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Antisense: 
 
Tau151-274 
5’TTACAGGATCCTCACTTCCCGCCTCCCGGCTGGTG3’ 
Tau151-305 
5’TTACAGGATCCTCAACTGCCGCCTCCCGGGACGTG3’ 
Tau151-336 
5’TTACAGGATCCTCACTGGCCACCTCCTGGTTTATG3’ 
Tau151-368 
5’TTACAGGATCCTCAATTTCCTCCGCCAGGGACGTG3’ 
Tau151-402 
5’TTACAGGATCCTCAGTCCCCAGACACCACTGGCGACTTGT3’ 
Tau151-412 
5’TTACAGGATCCTCAGGAGACATTGCTGAGATGCCG3’ 
Tau151-422 
5’TTACAGGATCCTCACGAGTCTACCATGTCGATGCT3’ 
Tau151-432 
5’TTACAGGATCCTCACACCTCGTCAGCTAGCGTGGC3’ 
Tau151-441 
5’TTACAGGATCCTCACAAACCCTGCTTGGCCAGGGA3’ 
 
Construct encoding for P2dGAE were made using the following primers: 
 
Sense: 5’GCCCGAATTCATGAGCAGCCCCGGCTCCCCAGGC3’ 
 
Antisense: 5’TTACAGGATCCTCACTCCGCCCCGTGGTCTGTCTT3’ 
 
Dr Luisa Fasulo prepared construct encoding for tau-head and Nt-dGAE 
(Fasulo et al., 2000).  
 
 
 
2.3.1 Cell culture, transfection and In Situ End-labeling of DNA (ISEL) 
with cell cultures 
COS simian fibroblasts were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum and High 
Glucose. Cells were transiently transfected by DEAE-dextran method as 
described (Fasulo et al., 1996) and analyzed 48 hours after the transfection 
for immunofluorescence and for western blotting analysis. 
MN7.51 hybridoma supernatant, which recognizes human tau (Novak et 
al., 1991) was used at 1:50 dilution. TRITC-conjugated rabbit anti-mouse 
(1:200 dilution, Vector) was used as secondary antibodies.  
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All the In Situ End-labeling of DNA (ISEL) with cell cultured were 
performed using the manufacturers’ instructions (ApopTag Direct in situ 
Apoptosis Detection kit, Oncor). 
Apoptotic transfected cells were counted 48 hours after transfection. 200 
transfected cells were examined on each coverslip.  
 
 
2.3.2 Preparation of cell extracts 
48-72 hour after the transfection, cells were washed three times with PBS 
(+Ca
2+
, +Mg
2+
), scraped with 1 ml of PBS, centrifuged for 3 min at 6000. 
Cells were resuspended in 500 µl of lysis buffer (50mM Tris pH 7.4, 2mM 
CaCl2, 1%NP-40 and cocktail of protease inhibitors) for 30 min at 4ºC 
rocking. Cells were centrifuged 5 min at 14000 rpm. 2XSDS gel-loading 
buffer and 10% β-mercaptethanol were added to the supernatant (and to the 
cellular debris). Samples were boiled before being analyzed by SDS-PAGE 
and western blot analysis 
 
 
 
2.4 Experimental Protocols For The Developing of The 
Intrabody Trap Technology (ITT) 
 
 
2.4.1 Vectors:  
 
τ 151-422/BTM116: the τ 151-422 EcoRI/BamHI fragment from τ 151-
422/pSG5 (Fasulo et al., 2000) was subcloned into EcoRI/BamHI sites of 
pBTM116. 
 
τ 151-274/BTM116, τ 151-305/BTM116, τ 151-336/BTM116, τ 151-
368/BTM116, τ 151-391/BTM116, τ 151-402/BTM116, τ 151-
412/BTM116 and dGAE/BTM116, were subcloned from the respectively 
pSG5 constructs, as described for τ 151-422/BTM116. 
 
 
τ 151-421/pMAL-c2: the DNA fragment τ 151-421 was PCR amplified 
from τ40/pSG5 (Fasulo et al., 1996) (Fasulo et al., 2000) using the primers: 
 
5’GCCCGAATTCATGATCGCCACACCGCGGGGAGC3’ (sense) 
5’GTCTCGCTAGAATTCGTCGACTCAGTCTACCATGTCGAT3’ 
(antisense).  
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The EcoRI/SalI digested fragment was cloned into pMAL-c2 (NEB) down-
stream from the malE gene, which encodes maltose-binding protein (MBP). 
This results in the expression of an MBP-fusion protein (di Guan et al., 
1988) (Maina et al., 1988).  
 
τ 151-422/pMAL-c2: the τ 151-422 EcoRI/BamHI fragment was 
subcloned into EcoRI/BamHI sites of pMAL-c2. 
 
scFv2/pUC119CAT, scFv14/pUC119CAT and scFv52/pUC119CAT: the 
scFv2, 14 and 52 SfiI/NotI fragment were subcloned from pVP16* 
plasmids into SfiI/NotI sites of pUC119 CAT. 
 
scFv2/scFvexpress, scFv14/scFvexpress and scFv52/scFvexpress: the 
scFv2, 14 and 52 NcoI/NotI fragment were subcloned from pUC119 CAT 
plasmids into NcoI/NotI sites of scFvexpress vectors (Persic et al., 1997). 
 
 
All the clones were sequenced using the Epicentre Sequitherm Excel II kit 
(Alsbyte, Mill Valley, CA) and analyzed on a Li-Cor 4000L automatic 
sequencer (Lincoln, NE). 
 
 
 
2.4.2 MBP fusion protein purification.  
This protocol is a modification made of published methods (Kellermann & 
Ferenci, 1982). 
The fusion protein was purified by one-step affinity purification for MBP 
as described: 
 
Day1: Inoculate 10 ml 2YT+2%glucose and 100 µg/ml ampicillin with few 
colonies containing the fusion plasmid 
 
Day2:  
1. Inoculate 600 ml 2YT+0.2%glucose and 100 µg/ml ampicillin with 
6 ml of the overnight culture of cells containing the fusion plasmid. 
2. Grow to 2-4x10
8 
cells/ml (O.D.600∼0.5) at 37°C, 250 rpm 
3. Add IPTG to a final concentration of 0.3mM 
4. Incubate the cells at 30°C, 250 rpm for 4 hours 
5. Harvest the cells by centrifugation at 5000 x g for 10 min. 
6. Discard the supernatant and resuspend the cells in 50 ml Column 
Buffer (30mM Tris-HCl pH 7.4, 200 mM NaCl, 1mM EDTA, one 
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tablet Complete, EDTA-free protease Inhibitor Cocktail Tablets, 
Boehringer Mannheim) 
7. Add Lysozime (0.1 mg/ml) and leave on ice for 30 min 
8. Freeze sample overnight at -20°C 
 
Day3: 
1. Thaw in cold water 
2. Add Dnase I (20 µg/ml) 
3. Place sample in a ice-water bath and sonicate for 2 min 
4. Centrifuge at 40000 rpm for 30 min. Save the supernatant 
5. Pour the amylose resin in a 2.5 x 10 cm column. Wash the column 
with 10 column volumes of Column Buffer 
6. Load the diluted crude extract at a flow rate of 1 ml/minute 
7. Wash with 20-30 column volumes of Column Buffer 
8. Elute the fusion protein with Elution Buffer (Column Buffer+ 10mM 
maltose) 
9. Collect 10 fractions of 500 µl each. The fusion protein start to elute 
within the first 5-6 fractions. 
10. Check on 10% SDS-PAGE, Coomassie stained, the fractions. Collect 
required fractions and dialyze over-night in 5L PBS buffer at 4°C; 
change buffer more than once if possible 
 
 
 
2.4.3 Preparation of Tau full-length protein 
BL21(DE3) bacterial cells (F
-
 ompT gal [dcm][lon] hsdSB (rB
-
mB
-
) with 
DE3, a λ prophage carrying the T7 RNA polymerase gene, expressing 
tau40/pRK172 were grown to 2-4x10
8 
cells/ml (O.D.600∼0.5) at 37°C in 600 
ml 2YT+0.2%glucose and 100 µg/ml ampicillin. IPTG to a final 
concentration of 0.4 mM was added and cells were then incubated for other 
four hours at 37°C. 
Bacterial cells were then pelleted, resuspended in phosphate buffered saline 
and boiled for 5 min. After centrifugation the supernatant containing 
thermostable tau was filtered (0.45 microns) and used in ELISA 
(Kontsekova et al., 1995). 
 
 
 
2.4.4 Western blot analysis 
Yeast and E.coli protein extracts were prepared as described before; 
samples were analyzed by SDS/PAGE followed by Western blot using the 
anti tau monoclonal antibody MN7.51 (Novak et al., 1991) or the anti tau 
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mAb Tau1 (Roche) and the polyclonal antibody anti lexA (for yeast extract 
only) (Clontech) as primary antibodies followed by anti-mouse-peroxidase 
conjugate (DAKO) and anti-rabbit-peroxidase conjugate (DAKO) 
respectively. The blots were developed by ECL method, according to the 
manufacturer’s instructions (Amersham, Arlington Heights, IL). 
 
 
 
2.4.5 Selection of phage antibody library 
A large non-immune phage antibody library kindly provided by J. Marks, 
Departments of Anesthesia and Pharmaceutical Chemistry, University of 
California, San Francisco (Sheets et al., 1998) was selected as described 
(Marks et al., 1992): 
1) To a 75 x 12 mm Nunc-immunotube (Maxisorp; Cat. No. 4-44202) add 
2 ml PBS and 10 mg/ml of 421MBP-purified protein. Leave overnight 
at 4°C to coat.  
2) Next day wash the tube 3X with PBS-Tween-20 (0.1%), 3X with PBS 
(simply pour solution in and pour out again immediately) 
3) Fill tube to brim with MPBS 2% (PBS containing 2% Marvel). Cover 
with parafilm and incubate at room temperature for at least 30 min to 
block. 
4) Prepare phage mix: 100 µl of PEG concentrated phage (∼1011-1012 TU) 
(aliquots were stored in 30% glycerol at –80ºC)+ 100 µl MBP purified 
protein (200 µg/ml) + 300 µl PBS and 500 µl of 4% MPBS. Store 
remainder of phage prep at 4°C 
5) Wash tube 2X with PBS-Tween-20 (0.1%), 2X with PBS 
6) Transfer phage mix from step 4 to the Immunotube. Seal tube with 
parafilm. Incubate 30 min at room temperature on under and over 
turntable and then stand for at least a further 1.5 hours at room 
temperature 
7) Wash tubes with 20 washes PBS-Tween-20 (0.1%) then 20 washes with 
PBS. Each washing step is performed by pouring buffer in and out 
immediately. 
8) Elute phage from tube by adding 1 ml 100 mM triethylamine (make 
fresh: 140 µl per 10 ml water, pH 12). Rotate the tube for 8 min on an 
under and over turntable 
9) Transfer solution to an eppendorf tube with 0.5 ml 1 M Tris-HCl, pH 
7.4 and mix by inversion to neutralize the phage eluate.  
10) Transfer to ice for later re-infection 
11) Grow TG1 E.coli  [K12, ∆(lac-pro), supE, thi, hsd∆5/F’traD36, 
proA
+
B
+
, lacI
q
, lacZ∆M15] to an O.D600 of 0.5 
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12) Add to 5 ml (2x10
9 
bacteria) TG1 500 µl of selected phagemid 
particles and let stand for 40 min at 37°C with occasional agitation 
13) After the infection event, spread the infected bacteria on 2YT, 100 
µg/ml ampicillin, 2% glucose plates 
 
After the first and the second cycle of selections, 96 scFv fragments present 
in individual colonies were identified by BstNI fingerprinting and the same 
isolated clones were used in Phage ELISA as described (Sblattero & 
Bradbury, 2000) to identify the number of different positive 421MBP 
binding scFvs. 
 
 
 
2.4.6 Growth and Rescue of Phagemid particles in 96-well microtitre 
plates 
 
Day1: 
1) Toothpick colonies into 150 µl 2YT, 100 µg/ml ampicillin, 2% glucose 
in 96-well flat-bottomed plates (Costar, Cat n. 3595) and grow with 
shaking (250 rpm) overnight at 30°C. This will be the master plate 
 
Day2: 
1. Transfer 2 µl (each single clone) from master plate to a fresh 96-well 
plate containing 150 µl 2YT, 100 µg/ml ampicillin, 2% glucose per 
well. Grow 2.5 hours, 37°C shaking. To the wells of the master plate, 
add 50 µl 60% glycerol per well and store at -70°C, after use. 
2. To each well add 50 µl 2YT, 100 µg/ml ampicillin, 2% glucose 
containing 2 x 10
9
 pfu M13K07 phage (0.1 µl of a 2 x 1013 pfu/ml 
stock per well). Let stand for 30 min at 37°C 
3. Spin at 600 rpm for 10 min; then remove supernatant and resuspend 
pellet in 150 µl 2YT, 100 µg/ml ampicillin, 25 µg/ml kanamycin. 
Grow overnight at 30°C shaking 
 
Day3: 
Spin at 600 rpm for 10 min and use 50 µl supernatant for phage ELISA 
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2.4.7 Induction of Soluble Antibody Fragments 
This method can also be applied for a 96-well microtitre plates: the 
recommended volumes can be referred to the previous phagemid rescue in 
a 96-well microtitre (see before). 
The scFvs were expressed from the plasmid pUC119CAT and pHEN in 
HB2151 non suppressor strain [K12, ara ∆(lac-pro), thi/F’ proA+B+, 
lackI
q
Z∆M15] 
 
Day1: 
Inoculate clones directly from the plate in 10 ml 2YT, 100 µg/ml 
ampicillin, 2% glucose. Incubate in a 30°C shaker overnight at 250 rpm 
 
Day2: 
1. Inject 5 ml of the overnight stock to 500 ml 2YT, 100 
µg/ml ampicillin, 0.1% glucose 
2. Incubate in a 37°C shaker at 250 rpm until bacteria reach 
O.D.600 of 0.6 
3. Induce with 0.5 mM IPTG 
4. Incubate in a 30°C shaker for 4 hours 
5. Collect cells by centrifuging in 500 ml plastic bottles at 
6000 rpm for 10 min 
6. Resuspend pellet in 12.5 ml PPB buffer (200 mg/ml 
Sucrose, 1mM EDTA, 30 mM Tris-HCl pH8, and one 
tablet Complete, EDTA-free protease Inhibitor Cocktail 
Tablets, Boehringer Mannheim). Keep on ice for 20 min 
7. Spin down cells in centrifuge at 5000 rpm for 15 min at 
4°C 
8. Collect supernatant  
9. Resuspend pellet in 12.5 ml of 5 mM MgSO4 buffer. 
Incubate on ice for 20 min 
10. Spin down cells in centrifuge at 5000 rpm for 15 min at 
4°C 
11. Collect the supernatant 
12. Load supernatants into dialysis tubing and dialyze 
overnight in 5L PBS buffer. Change buffer more than once 
if possible 
 
Day3: 
Collect the dialyzed soluble samples and store on ice until Ni-NTA agarose 
resin column purification 
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2.4.8 Purification of scFv Fragments on Ni-NTA Agarose Resin 
Column 
All the following steps are carried out at 4°C or on ice: 
 
Materials: 
• NaPi 0.1 M (233 ml/L Na2HPO4, 17 ml/L NaH2PO4) 
• WB1 (500 ml/L NaPi 0.1 M, 250ml/L NaCl 1M) 
• WB2 (500 ml/L NaPi 0.1 M, 500ml/L NaCl 1M) 
• WB3 (WB2 + 15 mM Imidazole) 
• EL (WB2+ 100 mM Imidazole) 
 
Procedure: 
 
1) Pre-equilibrate 2 ml 50% slurry of Ni-NTA agarose (Qiagen cat. N. 
30210): add 8 ml of PBS to resuspend the resin. Centrifuge at 800 
rpm for 5 min. Repeat twice this wash step. 
2) Load to the dialyzed periplasmic extract (equilibrated with NaCl, 
250 mM NaCl final concentration and pH 7.5) the washed resin and 
incubate rocking for 1-2 hours at 4°C 
3) Centrifuge at 800 rpm for 10 min. Wash the resin with WB1 (50 ml) 
4) Centrifuge at 800 rpm for 10 min. Resuspend the resin with 10 ml 
WB1 
5) Pour the resin into a 1 x 10 column  
6) Wash the column with 20-30 ml of WB2 
7) Wash the column with 20-30 ml of WB3 
8) Elute the scFv with the elution buffer EL. Collect 10 fractions of 500 
µl each. The scFv usually start to elute within the 5 fractions 
9) Analyze sample by SDS-PAGE and western blotting 
10) Dialyze the collected fractions into PBS as described before 
 
ScFv concentrations can be quantitated using the bicinchoninic acid kit 
(Pierce) according to the instructions of the manufacturer. 
 
 
 
2.4.9 ELISA for Detection of Soluble or Phage Antibody Fragments 
 
Day1: 
Coat plate with 100 µl per well of protein antigen (10 µg/ml in PBS). 
Leave overnight at 4°C 
Day2: 
1) Rinse wells 2X with PBS-Tween-20 (0.1%), 2X  with PBS 
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2) Block with 120 µl per well of 2% MPBS for 30 min at room 
temperature 
3) Wash by submersing the plate into buffer and removing the air 
bubbles in the wells by agitation 
4) Rinse wells 3X with PBS-Tween-20 (0.1%), 3X with PBS 
5) Add 50 µl of 4% MPBS 
6) Add 50 µl culture supernatant containing antibody fragment or phage 
antibody to appropriate wells. Mix by pipetting up and down and 
leave at room temperature for 1.5 hours 
7) Wash 3X with PBS-Tween-20 (0.1%), 3X with PBS 
8a) For soluble antibody detection: add 100 µl of 9E10 anti myc (Evan 
et al., 1985) antibody (1:50 dilution) in 2% MPBS into each well. 
Incubate at room temperature for 1 hour 
8b) For phage antibody detection: add 100 µl of anti fd-phage HRP 
conjugated (1:5000 dilution) in 2% MPBS to each well. Incubate for 1 
hour at room temperature 
9a,b) Wash 3X with PBS-Tween-20 (0.1%), 3X with PBS 
10a) Add 100 µl of anti-mouse antibody HRP in 2% MPBS. Incubate 
for 1 hour at room temperature 
11a) Wash 3X with PBS-Tween-20 (0.1%), 3X with PBS 
10b) 12a) Add 70 µl of TMB (Tecna s.r.l). Leave in dark at room 
temperature for 2-30 min. Quench by adding 70 µl H2SO4 2N. Read at 
450 nm 
 
 
 
2.4.10 Construction of an Activation Domain-Fusion anti 421MBP 
scFv library 
 DNA phagemids from the first and the second cycle of phage antibody 
selection was extracted (Qiagen midiprep kit) and scFv fragment DNA was 
subcloned into SfiI/NotI sites of pVP16*. The ligation mix was 
electroporated into electrocompetent DH5αF’ (Gibco BRL, Rockville, 
MD) [F’/endA1 hsdR17(rK-mK+) supE44 thi-1 recA1 gyrA (Nal
r
) relA1 
∆(lacZYA-argF)U169 deoR (φ80dlac∆(lacZ )M15] and plated on LB 
100µg/ml ampicillin plates to obtain the AD-library.  
The final libraries are calculated to have a diversity of approximately 
2.2x10
6 
for the first cycle and 6x10
4 
for the second cycle respectively. 
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2.4.11 Selection of intracellular antibodies using the two-hybrid system 
The AD-fusion anti 421MBP scFv library was transformed in L40 yeast 
containing 422/BTM116 bait plasmid following a maxi-scale LiAc 
transformation protocol, as described before. After the scoring of His+ 
yeast colonies, a X-Gal lift assay was performed as described before.  
100 individual AD-fusion scFv plasmids were isolated from segregated 
yeast cells and scFv inserts were identify by BstNI fingerprinting and by 
sequencing as described before. 
The isolated AD-fusion scFv plasmids were cotransformed with the LexA-
422 antigen bait vector into L40 yeast strain by using a small-scale LiAc 
transformation protocol and reselected by using auxotrophic markers for 
both plasmids and for lysine and histidine prototropy and by X-Gal lift 
assay.  
 
 
 
2.4.12 Analytical Gel filtration 
Gel filtration was carried out on a Superdex 75 column (Amersham 
Pharmacia Biotech, UK). All the measurements were carried out in PBS 
buffer. The respective scFv fragments were injected at 50-200 µg/mL in a 
volume of 200 µL. The column was calibrated in the same buffer with 
molecular mass standards. The incubated samples were centrifuged for 5 
min at 14000g before applying them to the column to remove large 
aggregates, which might block the column. 
 
 
 
2.4.13 Competition ELISA 
 Prior to conventional ELISA 40nM of individual scFvs were incubated for 
one hour at room temperature with increasing amounts (100nM to 1µM) of 
purified 422MBP, MBP and tau40 respectively. After incubation of scFvs 
with antigens, the unbound scFvs are detected by ELISA using the mouse 
anti-myc monoclonal antibody 9E10 (Evan et al., 1985) as primary 
antibody and the anti-mouse-peroxidase conjugate (DAKO) as secondary 
antibody. The ELISA were developed by TMB method, according to the 
manufacturer’s instructions (Tecna s.r.l). 
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2.4.14 Cell line, transfection and immunofluorescence analysis 
CHO Chinese Hamster Hovary Cells were grown in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 
High Glucose and Proline (17.2 mg/L final concentration). 
Cells were transiently transfected by FuGENE-6 Transfection Reagent 
(Roche) method according to the manufacturer’s instruction (Roche) and 
analyzed 30-48 hours after the transfection for the immunofluorescence and 
for western blotting analysis. 
COS simian fibroblasts were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum and High 
Glucose. Cells were transiently transfected by DEAE-dextran method as 
described (Fasulo et al., 1996) and analyzed 30-48 hours after the 
transfection for immunofluorescence and for western blotting analysis. 
MN7.51 hybridoma supernatant, which recognizes human tau (Novak et 
al., 1991) was used at 1:50 dilution. mAb anti-myc antibody 9E10 (Evan et 
al., 1985) and polyclonal anti-myc (Clontech) were used in dilution 1:50 
and 1:40 respectively. TEXAS-RED-conjugated anti-mouse (1:50 dilution, 
Vector) fluorescein anti-mouse conjugate (1:50 dilution, Vector) or anti-
rabbit immunoglobulins fluorescein-conjugate (1:50 dilution, Vector) was 
used as secondary antibodies. Nuclei were stained with the fluorescent dye 
DAPI (Boehringer Mannheim) following the manufacturer’s instructions. 
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Chapter Three: The development of an in vivo 
assay for functional intracellular antibodies using 
the two-hybrid approach 
 
 
3.1 Introduction 
 
The virtually unlimited repertoire of immunoglobulins is widely used as a 
source of specific reagents for biochemical or physiological studies in 
which specific gene products can be inhibited or modulated in vitro. 
The advances in molecular immunology and the development of phage 
display library techniques provide conditions for the generation of large 
numbers of human antibodies with desired specificities and functional 
activity. 
The potential of using antibodies to interfere with biological processes 
inside the cell in a highly specific manner has been successfully 
demonstrated. Intrabodies can be used in different experimental strategies 
to specifically interfere with function of selected intra- or extracellular gene 
products in mammalian cells.  
Intracellular immunization approaches are receiving great attention for 
application to gene therapy and for functional genomics, as this thesis will 
demonstrate.  This approach suffers however from drawbacks and 
limitations represented by the fact that the environment in which the 
antibodies are naturally selected is very different from the one in which 
prospective intrabodies are asked to work.  
In particular, when antibodies are expressed in the cell cytoplasm, folding 
and stability problems often occur, resulting in low expression level and 
limited half-life of antibody domains.  
To overcome these limitations, a general strategy for selecting antibodies 
that are stable and soluble under intracellular expression conditions is 
needed. 
The first step of this work was the developing of a general antibody-antigen 
two-hybrid system.  
In order to practically test the system, we have monitored a panel of scFv 
derived either from mAbs or from phage display antibody libraries, some 
of which had been shown to have biological activity when intracellularly 
expressed in vivo. 
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3.2 Results 
 
 
3.2.1 The Antibody-Antigen Two-Hybrid System  
The yeast two-hybrid system was adapted to monitor the interaction of 
scFv fragments with their corresponding antigens, under condition of 
intracellular expression. The procedure is outlined in Fig 3.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.1 Dual selection/screen by using the two-hybrid system. A) The 
antigen (Ag) fused to the DNA-binding domain of the E.coli repressor LexA is 
expressed in the yeast strain L40 carrying two reporter genes, lacZ and HIS3, under 
control of the LexA regulatory sequence. This hybrid protein can bind to its operator 
site but will not activate transcription. A second plasmid, which expresses the scFv 
fragments fused to the herpes simplex virus VP16 transcriptional activation domain, is 
introduced into the same strain; this hybrid protein does not bind to the upstream 
activation sequence (UAS) because it lacks the DNA-binding domain. B) The 
interaction of the activation domain fusion scFv with the DNA-binding fusion Ag 
results in the expression of the reporter construct. 
 
Ag
scFv
Activation domain
DNA-binding
domain
UAS TATA
OFF
Reporter gene: HIS 3 and or lacZ
Ag scFv
UAS TATA
Reporter gene: HIS 3 and or lacZ
ON
A)
B)
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The expression vectors used for this purpose were obtained by cloning the 
in frame sequence of a target antigen at the 3’end of the E.coli repressor 
protein lexA (Bartel et al., 1993) to construct the DNA binding domain 
fusion protein and by cloning the in frame sequences of scFv at the 5’end 
of the activation domain of the herpes simplex virus 1 VP16 transcription 
factor (Hollenberg et al., 1995) (See figure 2.1 and 2.2 respectively). 
Two nuclear localization signals are located on the scFv-VP16 fusion 
protein, whereas the antigen bait has none (Silver et al., 1986) (Hollenberg 
et al., 1995). Therefore, the interaction between the antigen and the scFv 
fragment could occur in the cytoplasm (some small lexA-fusion antigens 
could be small enough to diffuse into the nucleus and to locate to their 
operator sites), before the complex is translocated to the nucleus and 
activates transcription. 
These vectors were cotransfected into L40 yeast cells, carrying the yeast 
biosynthetic gene HIS3 and the bacterial gene lacZ under the control of a 
minimal promoter with LexA binding site.  
If the scFv antibody fragment binds to the antigen target in vivo, a complex 
formed between the scFv fragment and the antigen can bind to the HIS3 
promoter (via the DNA-binding part of the lexA-antigen fusion protein) 
and activate transcription (via the activation domain of the VP16-scFv 
fusion protein). This interaction will restore histidine independent growth 
of the yeast (Fig. 3.1 B). 
The selection for interacting clones was carried out by both nutritional 
selection for histidine and an assay for β-galactosidase activity. 
As a model system, we have chosen the very well characterized scFv F8. 
This scFv antibody recognizes a highly conserved site on the coat protein 
p41 that is involved in divalent-cation regulated swelling of the artichoke 
mottle crinkle virus (AMCV) (Tavladoraki et al., 1993). 
It was previously shown that the constitutive expression of this 
monoclonal-derived scFv fragment in transgenic Nicotiana benthamiana 
plants, causes reduction of infection incidence and delay in symptom 
development following AMCV infection (Tavladoraki et al., 1993). 
Before testing the interaction between the scFvF8 and its relative antigen, 
the expression level of both fusion protein was assessed in L40 yeast cells 
by western blot analysis using a polyclonal anti-lexA protein (Invitrogen) 
for bait construct and the anti-myc-tag mAb 9E10 (Evan et al., 1985) for 
scFv-VP16 fusion protein (Fig.3.2 a and b, respectively). 
Co-expression of the lexA-AMCVp41 bait and the scFvF8-VP16 fusion 
protein in L40 yeast cells, results in the transcription of reporter genes that 
confer the His
+
 and the blue phenotype on the host cells (Fig.3.3 row 4). 
The transfection of the bait lexA-AMCVp41 alone or with the activation 
domain vector VP16 or of an unrelated antigen fusion lexA-lamin with the 
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scFvF8 fusion, did not result in activation of both reporter genes (Fig. 3.3, 
row1, 2 and 3 respectively). 
These results demonstrate that the scFvF8 is able to specifically interact 
with its corresponding antigen under intracellular expression conditions in 
yeast cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.2 Western blot analysis of lexA-AMCVp41 bait and control 
extracts (a) and scFvF8-VP16 and control extract (b). Samples were prepared in SDS-
PAGE loading buffer with β-mercaptoethanol as described in chapter 2. After blotting, 
the fusion protein was detected with the anti-lexA (a) and with the anti-myc antibody 
9E10 (b). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.3 lexA-AMCVp41 bait + scFvF8-VP16 prey. L40 yeast cells were co-
transformed with a lexA-AMCVp41 antigen bait vector (AMCVp41/BTM116) and 
scFvF8/VP16* fusion vector (row 4) or the pVP16* vector alone (row 2). β-
galactosidase activation was observed only when the lexA-AMCVp41 bait was 
coexpressed with scFvF8/VP16* (row 4).  
VP16 
scFvF8-
VP16 
65 
45 
30 
MW(Kdal) MW(Kdal) 
65 
45 
30 
L40 lexA 
lexA-
AMCVp41 
a) b) 
lexA-AMCVp41 
lexA-AMCVp41 + VP16 
lexA-Lamin + VP16 
lexA-AMCVp41 + scFvF8-VP16 
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3.2.2 The Yeast Antibody-Antigen Two-Hybrid System Can 
Distinguish Intracellular Binders 
In order to verify the general use of the antibody-antigen two-hybrid 
system, a panel of scFv fragments (see panel below) derived either from 
monoclonal antibodies or from phage display antibody libraries was tested. 
 
scFv IN33: 
The intracellular expression of the monoclonal-derived scFvIN33, which 
bind to catalytic and carboxy-terminal domains of the virus-encoded 
enzyme integrase (IN), results in resistance to productive HIV-1 infection. 
This inhibition of HIV-1 replication is observed with the scFv localized in 
either the cytoplasmic or nuclear compartment of the cell. The expression 
of anti-IN scFv fragment in human T-lymphocytic cells and peripheral 
blood mononuclear cells appears to specifically neutralize IN activity prior 
to integration and, thus, has an effect on the integration process itself 
(Levy-Mintz et al., 1996). 
 
scFv V6C11, scFv G6G2, scFv G4G11: 
These three scFv fragments, directed against the non-receptor protein-
tyrosine kinase Syk, were isolated from a large naive phage display single-
chain antibody library (Vaughan et al., 1996). They react with Syk in 
ELISA, immunoprecipitation, immunofluorescence and western blot 
(Peneff et al., 2000) 
 
scFv Y13-259: 
The monoclonal-derived anti-p21ras Y13-259 scFv fragment has been 
shown to inhibit the insulin induced meiotic maturation in Xenopus oocytes 
(Biocca et al., 1993) (Biocca et al., 1994), and the intratumor transduction 
of HCT116 colon carcinoma cells with this scFv fragment, using an 
adenovirus vector, leads to tumor regression in nude mice (Cochet et al., 
1998). Furthermore, the expression of anti-p21ras Y13-259 scFv fragment 
in 3T3 fibroblast cell line neutralizes the activity of p21ras (Cardinale et 
al., 1998). 
 
scFvs anti p21-ras: 
Twelve scFv fragments, directed against p21-ras protein (Persic et al., 
1999), were isolated from a large naive phage display single-chain library 
(Sheets et al., 1998). They react with the 57-76 p21-ras neutralizing epitope 
in ELISA and in western blot. The binding affinity of each scFvs, 
determined by plasmon resonance, was in the range of 5-800 nM (Lener et 
al., 2000). 
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All the baits used in these assays were individually assessed for auto-
activation of the two reporter genes, with or without the pVP16* vector as 
demonstrated in Fig. 3.4 a), b) and c) (first and second row respectively). 
All the baits used, were unable to grow in the absence of histidine (data not 
shown) and they didn’t turn blue, also in the presence of the empty vector 
pVP16*, when β-gal assay was assessed. 
When anti-HIV scFv fragment was expressed as VP16 fusion protein with 
the lexA-HIV-IN bait in L40 yeast cells, the activation of HIS3 reporter 
gene and a high level of β-gal activity was observed (Fig.3.4 a, row 4) 
whereas, the expression of the same scFv with the non-relevant antigen 
lamin, did not result in any activation (Fig.3.4 a, row 3). 
To determine whether scFv selected from phage display libraries in vitro 
could function in the antibody-antigen two-hybrid assay, three phage-
derived scFv fragments were tested. 
Only one of these, scFv G4G11, shows a positive interaction with its 
relative antigen (Fig.3.4 b, row 8) while the other two failed to interact 
(Fig.3.4 b, row 6 and 7). The specificity of this scFv interaction with the 
lexA-Syk bait was established with the lamin bait (Fig.3.4 b, row 5). 
This observation reinforce the idea that scFv selected in vitro from a phage 
display library, purely for their ability to bind antigen, may not necessarily 
function correctly as intracellular antibodies. This result point out the 
inadequacy of the in vitro selection in fishing out possible functional 
candidates for intracellular expression. 
When scFvY13-259 was used in two-hybrid assay with the lexA-K-ras 
fusion bait, it failed to activate the HIS3 and lacZ reporter genes at 30°C 
(Fig.3.4 c, row 4) but was able to induce growth in the absence of histidine 
or β-gal activity at 20°C (Fig.3.4 c, row 5). This interaction was specific for 
K-ras and not for the lamin bait at both temperature (Fig.3.4 c, row 3), and 
the K-ras bait did not auto-activate the reporter genes when expressed alone 
or in the presence of the pVP16* empty vector (Fig.3.4 c, row 1 and 2 
respectively). 
Another demonstration that not all the scFv fragments isolated from a 
phage display library are able to bind their antigen when expressed 
intracellularly in two-hybrid system was assessed testing several distinct 
scFv fragments for p21-ras. Only 2 scFvs among 12 were able to interact 
with the K-ras bait even when tested at 20°C (data not shown). 
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Fig.3.4 Intracellular expression of a panel of scFv fragment in the yeast 
two-hybrid system. L40 yeast cells were cotransformed with a panel of lexA-
antigen DNA-BD and scFv-VP16 fusion transcriptional AD pairs. 
Yeast were streaked and grown on his- medium and scored for β-gal activity. a) 
Transformation of lexA-HIV-1 IN alone (row1), lexA-HIV-1IN with pVP16* vector 
(row2), or with scFvIN33-VP16 (row4). β-gal activation was scored only when 
scFvIN33-VP16 was cotransformed with lexA-HIV-1IN (row4) and not when it was 
cotransformed with the non-relevant antigen lamin (row3). b) Transformation of lexA-
Syk bait, alone (row1) or with pVP16* vector (row2). In rows 3-5 specificity of 
scFvV6C11, scFvG6G2 and scFvG4G11 was assessed with the lexA-bait lamin. In rows 
6-8, the same three scFvs were cotransformed with the lexA-Syk bait. β-gal activation 
was observed only for scFvG4G11 (row8). c) Transformation of lexA-K-ras bait alone 
(row1) or with the pVP16* vector alone (row2). In row 3, specificity for scFvY13-VP16 
was assessed with the non relevant antigen lamin at 20°C (row3) and with the lexA-K-
ras bait at 30°C (row4) or 20°C (row5). β-gal activation was observed only in row 5. 
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3.2.3 Redox state of scFv fragments 
The folding and the stability of antibodies in the cell cytoplasm is not 
constant, as revealed by the number of experiments performed so far in 
several intracellular contexts. Therefore, there is a need to isolate the subset 
of scFv fragments that can bind the corresponding antigen inside the cell. 
As demonstrated before, the two-hybrid assay for intracellular antigen-
antibody interactions should allow the isolation of antibody domains that 
tolerate the reducing cytoplasmic and nuclear expression conditions. In 
order to prove that a positive outcome of antigen-antibody interaction in the 
two-hybrid format does indeed occur in the absence of disulphide bond 
formation, we have investigated the redox state of the scFvF8 fusion 
protein under yeast expression conditions. A gel mobility assay (Biocca et 
al., 1995) was performed in order to compare protein extracts under 
reducing or non-reducing conditions. The western blot analysis revealed no 
difference in the mobility of the scFvF8-VP16 fusion protein in both 
reducing and non-reducing conditions, while the control scFv expressed in 
the endoplasmic reticulum of insect cells revealed a clear gel shift between 
the two conditions (Fig.3.5). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.5 Redox state of scFv fragments. Samples were prepared in SDS-PAGE 
loading buffer containing β-mercaptoethanol (+ β-mer) or not β-mercaptoethanol (-β-
mer). After blotting, the proteins were detected by using the anti myc-tag mAb 9E10 β-
mer (Evan et al., 1985). The bars at the right of the lanes indicate the molecular mass 
gel shift between the oxidized (ox) and reduced (red) forms of the scFvαD11. scFvF8-
VP16 fusion protein does not show a shift in electrophoretic mobility, between reducing 
and non-reducing conditions, indicating that no disulphide bond occurs in the yeast 
cytoplasm (RED). 
 
The success of the interaction between the scFvF8 and its relative antigen 
in yeast cells, reinforced by the evidence that no disulphide bonds is 
formed, under those conditions, suggested us to consider the scFvF8 an 
ideal molecule with which to perform a model selection. This in vivo 
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experiment should show whether the yeast antibody-antigen two-hybrid 
system could be applicable to antibody selection strategies. 
 
 
3.2.4 Model Selection 
In order to perform this experiment, the scFvF8-VP16 fusion plasmid was 
diluted with DNA from a library encoding non-relevant scFvs-VP16. A 
DNA mixture in which 1 part of scFvF8 was added to 5x10
5 
parts of scFv 
library was obtained and DNA plasmids of this mixture were 
cotransformed in L40 yeast cells, using a LiAc maxi-scale transformation 
protocol. After transformation, cells containing the mixed scFvF8 + scFv 
library plasmids, encoding the scFvF8 interacting with AMCVp41 bait, 
were selected on histidine deficient plates. After 3 days, 84 independent 
colonies from 1/40 of the transformation mix were rescued from his- plates. 
These colonies were picked and replated on his-plates for screening for β-
gal activity. Among 48 colonies, 22 developed a strong blue color 
(Fig.3.6). 10 blue colonies were taken for further DNA restriction analyses 
and sequences. The restriction pattern obtained after the BstNI digestion of 
isolated plasmid DNA from blue yeast transformed cells revealed an 
identical pattern with scFvF8 starting material (Fig.3.7). The sequences 
performed with the same 10-isolated DNA plasmid confirmed those data 
(data not shown). 
The result obtained with this experiment demonstrate the feasibility of this 
system to select interacting scFv from a dilution of up to 1 in 500000, 
indicating that selection with even higher dilutions are feasible by scaling 
up the number of yeast transfected colonies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.6 Model selection. L40 yeast 
cells were cotransformed with lexA-
AMCVp41 bait with a mixture of DNA 
of a dilution of 1:500000 of scFvF8-
VP16 in scFv-VP16 DNA library 
respectively. Yeast were plated onto –his 
plates and incubated for three days at 
30°C. Strongly activating interactions 
were detected by HIS3 transactivation. 
His+ colonies were transferred from the 
master plate to a new –his plate for the β-
gal filter assay. 22 colonies developed a 
strong blue color indicating the presence 
of the interaction between lexA-
AMCVp41 fusion bait and its relative 
scFvF8-VP16 transactivation fusion 
protein. 
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Fig.3.7 Fingerprinting analysis of isolated yeast blue colonies. Single 
colonies after HIS3 transactivation, were selected, and scFv were PCR amplified using 
a set of primers designed to amplify V genes (Sblattero & Bradbury, 1998). BstNI 
fingerprinting analysis shows the presence of scFvF8 in all the scored plasmids. On the 
right the scFv-VP16 plasmid was used as a control in the experimental conditions. 
 
 
 
3.3 Discussion 
 
 
The potential of the intracellular use of antibody fragments to inhibit 
protein function has been demonstrated in several experimental 
applications (Biocca et al., 1993) (Richardson et al., 1995) (Cochet et al., 
1998) and the future applications of this approach in gene therapy and in 
functional genomics must not be underestimated. 
While satisfactory scFv fragment for in vitro studies can be selected by 
using large phage antibody libraries, it is clear that not all the in vitro 
isolated scFv fragments can be specifically functional in vivo, particularly 
in some cell compartment such as the cytoplasm. 
The ability to use scFv fragments in vivo as intracellular antibodies is 
restricted by their ability to fold correctly and stably in the reducing 
environment of the cell cytoplasm.  
Many residues in the frameworks contribute to the folding stability of 
antibody domains. Recent quantitative studies on the stabilizing role of the 
intrachain disulphide bond in immunoglobulin variable regions have shown 
that removal of this covalent bond has a destabilizing effect in the order of 
approximately 4.5 kCal/mol. Therefore, those scFv fragments which are in 
the upper range of folding stability will tolerate the loss of intrachain 
disulphide bond and remain folded (Fig.1.8), while those that are in the 
1 2 3 4 5 6 7 8 9 10 F8 
φX 
HaeIII 
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lower range, will unfold. The latter, can be stabilized by mutations in the 
framework, and thus made tolerant to the absence of disulphide bonds. 
These results, altogether, suggest that the antibodies in the upper part of the 
folding stability range are good candidates for intracellular expression. 
However, folding stability under reducing conditions is not the only 
parameter important for a good intracellular expression, solubility versus 
propensity to aggregate, cellular half-life and affinity being some of the 
most relevant properties of antibodies that will greatly affect their 
performance when intracellularly expressed. It can take much work and 
long time to discover that a particular antibody is not able to interact 
efficiently with its corresponding antigen in the cytoplasm. Therefore, there 
is a need for a selection system that could rapidly predict the performance 
of antibody fragments under conditions of intracellular expression. 
A proof of principle for selection schemes based on the phenotype provided 
by an intracellular antibody has been recently assessed for mammalian cells 
(Gargano & Cattaneo, 1997b). More recently, a phenotypic selection 
scheme for intracellular antibodies in the cytoplasm of E.coli cells has been 
described (Martineau et al., 1998) and this selection scheme was used to 
select a scFv variant with greatly improved expression properties. 
However, phenotypic selection schemes for cytoplasmic antibodies are 
limited to the particular system under study. The challenge is to develop 
more general selection schemes.  
With this purpose, the first part of the project was aimed at developing a 
selection scheme for the isolation of intracellular antibodies, based on their 
ability to bind antigen under conditions of intracellular expression, in the 
yeast two-hybrid format. 
We tested a panel of scFv fragments, some of which had been previously 
used as intracellular antibodies, while others not. All those fragments that 
were previously shown to induce a well-controlled biological phenotype 
when intracellularly expressed in different systems were also positive in the 
two-hybrid system. The only partial exception to this statement is provided 
by the Y13-259 scFv fragment, which, in the two-hybrid format, is only 
positive at 20°C, and not at 30°C. It is noteworthy that the initial 
intracellular expression experiments performed with this antibody were 
performed in Xenopus laevis oocytes (Biocca et al., 1993), at 18°C. We 
now know that this scFv fragment, at higher temperatures, forms 
intracellular aggregates in the cytoplasm of cells (Cardinale et al., 1998). 
On the other hand, not all the scFv fragments tested are positive in the two-
hybrid system, on the contrary, quite a few of them are negative, even if 
their binding affinities are comparable to that of the scFv fragments that 
work. This confirms the utility of a simple and quick selection procedure 
for intracellular antigen-antibody interactions and the model selection 
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described demonstrates the feasibility of isolating, from an antigen-
enriched polyclonal phage antibody population, those scFv fragments able 
to interact intracellularly with the antigen.  
This result provided the demonstration that antigen-specific scFv fragments 
can be easily isolated from a large pool of scFvs specificity using this 
approach. This technique can obviate the need for scFv engineering, such 
as random or direct mutagenesis, or CDR grafting on stable frameworks, 
and may represent a valid alternative in functional knock-out on a wide 
genomic scale. 
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Chapter Four: Alzheimer’s Disease: Mechanism of 
Neuronal Degeneration 
 
 
 
The experimental procedures described in this thesis have allowed the 
selection of intrabodies against the protein tau (see chapter five), a protein 
that is involved in Alzheimer’s disease. 
During the first part of my work I was devoted to look at the general impact 
of tau fragments on cell viability (Fasulo et al., 2000). This chapter will 
briefly introduce the involvement of tau protein in Alzheimer’s disease and 
summarize the work performed by myself in that project. 
 
 
 
4.1 Introduction: Major pathological hallmarks of Alzheimer’s disease 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder, which affects 5 
to 10% of all people over 65 years of age. Patients suffering from 
Alzheimer’s disease develop a progressive dementia in adulthood, 
accompanied by three main structural changes in the brain: 
• Diffuse loss of neurons in the hippocampus and neocortex 
• Accumulation of intracellular protein deposits termed neurofibrillary 
tangles (NFTs) 
• Accumulation of extracellular protein deposits termed amyloid or 
senile plaques (SP), surrounded by misshapen nerve terminals 
(dystrophic neurites or DN) (St George-Hyslop & Westaway, 1999). 
 
The neurofibrillary tangles are considered to be a major pathological 
hallmark of Alzheimer’s disease; NFTs develop within the pyramidal 
neuronal soma as filamentous inclusions and may extend into dendrites.  
In AD brain the nerve cells can degenerate and it appears that they die 
because they contain neurofibrillary lesions. These lesions are found in 
nerve cell bodies and apical dendrites as NFTs, in distal dendrites as 
neuropil threads and in abnormal neurites, which are often, but not always, 
associated with amyloid plaques. 
Neurofibrillary lesions consist of paired helical filaments (PHFs), paired 8-
20 nm filaments tightly wound into helices with periodicity of 80 nm 
(Wisniewski et al., 1976) form of dispersed filaments (Greenberg & 
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Davies, 1990) (Lee et al., 1991), and the related straight filaments (SFs), as 
their minor fibrous components (Spillantini & Goedert, 1998). 
PHF are highly stable structures that can withstand protease digestion: they 
consist of 4-8 100-micron protofilaments, appeared as twisted ribbons 15-
20-nm and 21-23-nm, left handed double helices, with periodicity of 160 
nm, without significant internal substructure (Tracz et al., 1997) containing 
proteins that are immunologically related to normal cytoskeletal proteins. 
While the dispersed filaments are soluble in guanidine or SDS, the majority 
of tangle fragments PHFs are insoluble in these reagents. Pronase treatment 
of tangle preparations removes a fuzzy coat from the PHF and leaves 
behind a pronase-resistant core.  
The principal constituent of PHFs is tau protein (Kosik et al., 1986) 
(Grundke-Iqbal et al., 1986) (Ksiezak-Reding et al., 1987) (Nukina & 
Ihara, 1986), which represent the protein chosen for testing the technology 
developed in this study: the next paragraphs will describe the pathology in 
neurodegenerative disease of this protein. 
 
 
4.1.1 Tau Protein: Physiological Functions 
Tau is a developmentally regulated microtubule-associated protein (MAP).  
Tau protein is prominent in neurons, particularly in axons, and one of its 
roles is thought to be the stabilization of microtubule arrays (Drubin & 
Kirschner, 1986). 
It is encoded by a single gene located on the long arm of chromosome 17 at 
band position 17q21 (Neve et al., 1986). 
The tau primary transcript contains 16 exons but 3 are not present in human 
brain (exon 4A, 6 and 8). They are specific to peripheral tau proteins. 
In adult human brain, six tau isoforms, 352-441-residue proteins with 
apparent molecular masses ranging from 48 to 67 kDa have been identified. 
They are produced by complex alternative mRNA splicing of 11 exons 
(Himmler, 1989) (Andreadis et al., 1992). 
These isoforms differ by the presence or absence of one or two (29 or 58 
amino acids long, respectively) NH2 inserts and by a COOH region with 
three (3Rtau) or four (4Rtau) imperfect 18-amino acid microtubule (MT)-
binding repeats, each of which is separated by an interrepeat domain of 13 
or 14 amino acids (Goedert et al., 1989). 
There is also a larger tau isoform, with an additional 254 amino acid insert 
in the amino-terminal region, which is mainly expressed in the peripheral 
nervous system (Goedert et al., 1992). 
Fetal human brain expresses only a shortest tau isoform, which lacks both 
amino-terminal inserts and the fourth carboxy-terminal microtubule-
binding motif (Goedert et al., 1989). 
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Fig.4.1  Tau Isoforms and Composition 
 
 
Tau promotes tubulin assembly in vitro (Weingarten et al., 1975) and 
stabilizes microtubules against depolymerization in vivo (Drubin et al., 
1985) (Kanai et al., 1989). 
The presence of tau antisense in primary neuronal cell culture appears to 
block the development and maintenance of axon-like processes, suggesting 
a role in the establishment of neuronal polarity (Caceres & Kosik, 1990) 
(Caceres et al., 1991). 
Tau has been considered to have a role in neurite elongation (Drubin et al., 
1985) (Drubin & Kirschner, 1986) and infection of Sf9 cell with a 
baculovirus expressing human tau markedly alters the morphology of the 
host cells, inducing long axon-like processes and microtubule bundles 
(Knops et al., 1991). 
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On the basis of its ability to promote microtubule assembly and stability in 
vitro, tau has been proposed to promote microtubule assembly and 
stabilization in growing axons (Brandt & Lee, 1993). 
Tau is a phosphoprotein and its mobility on SDS-PAGE is slowed by 
phosphorylation. Fetal tau is highly phosphorylated and shows 
immunoreactivity with several phosphorylation-sensitive antisera 
(Billingsley & Kincaid, 1997). 
The binding of tau to microtubules is regulated by a “physiological” 
phosphorylation. 
The discovery that highly phosphorylated tau protein is the major 
component of the paired helical filaments (PHFs) of AD and other 
neurodegenerative disease has focused attention on the nature and 
enzymology of the post-translational modification of this particular 
microtubule-associated protein (Goedert et al., 1993). 
 
 
 
4.1.2 Tau Protein: Pathological Aberrations 
Tau is the major component of the filamentous neurofibrillary lesions of 
AD and other tauopathies. 
This protein extracted from PHF exhibits features of postranslational 
modifications, including: 
• Phosphorilation 
• Ubiquitination (Mori et al., 1987) 
• Glycation (Ko et al., 1999)  
• Glycosylation 
• Proteolysis 
This raises the possibility that accumulation of aberrant-modified tau may 
play a crucial role in tangle formation leading to dysfunction, degeneration 
and ultimate death of affected neuron in AD. 
PHF that accumulate in affected neurons in AD are comprised of 
hyperphosphorylated tau that exhibits electrophoretic and antigenic 
properties distinct from that of normal adult CNS (central nervous system) 
tau (Goedert et al., 1993).  
At least 25 phosphorilation sites have been identified in the PHF-tau (Iqbal 
et al., 1986) (Goedert, 1993). These sites can be classified as either proline-
directed or nonproline-directed phosphorylation sites (Morishima-
Kawashima et al., 1995) (Song & Yang, 1995). Both types of 
phosphorylation can affect tau’s function. 
It is commonly assumed that the hyperphosphorylation of tau causes its 
detachment from microtubules and promotes its assembly into PHFs; in 
fact it was shown that PHF-tau exhibits a decreased microtubule (MT) 
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binding activity, and dephosphorylation dissociates PHFs and restores 
microtubule-assembly promoting properties to tau (Iqbal et al., 1986) 
(Wang et al., 1995). A decrease in the tau phosphatase activity in AD 
brains has also been shown, suggesting that tau is abnormally 
hyperphosphorylated in AD brains, probably due to an imbalance in the 
protein phosphorylation/dephosphorylation systems (Gong et al., 1993) 
(Gong et al., 1995) (Matsuo et al., 1994) (Garver et al., 1996). 
It is still impossible to confirm at present whether in AD tau is first 
hyperphosphorylated, which induces its dissociation from microtubules, 
leading in turn to their collapse, or whether MT collapse represents an 
initiating phenomenon, and newly-dissociated tau subsequently becomes 
hyperphosphorylated. Furthermore, recent studies suggest that the 
hyperphosphorylation of tau in AD is not directly responsible for the 
pathological aggregation into PHFs, (Schneider et al., 1999) and the results 
of the effect of two kinases (MAPK and GSK-3) on tau-microtubule 
interactions revealed that this kind of phosphorylation never enhanced 
aggregation but, on the contrary, protected against it. This last observation 
reinforces the assumption that hyperphosphorylation of tau is unlikely to be 
directly responsible for the pathological aggregation of tau in AD. 
The aggregates of hyperphosphorylated tau and normal tau work as “seeds” 
for the polymerization of tau into neurofibrillary tangles in which PHF are 
formed after glycosylation of tau, another abnormal posttranslational 
modification present on AD-tau (Wang et al., 1996). 
In AD the glycosylation of tau, a cytoplasmic protein, raises an intriguing 
possibility of a membrane abnormality whereby tau and a specific 
glycosyltransferase, normally separated in different cell compartments, 
become accessible to each other.  
PHF retains, after digestion with pronase, its characteristic protease-
resistant core, which is formed by a group of 12 Kdal tau fragments that 
encompass the microtubule-binding repeat regions (Wischik et al., 1988a; 
Wischik et al., 1988b). These fragments are unable to bind to microtubules 
and to induce their bundling when expressed in vivo, but do not affect 
either cell morphology or viability (Fasulo et al., 1996). 
Core PHFs have been used to raise the monoclonal antibody MN423 
(Wischik et al., 1988b) (Novak et al., 1989), which specifically stains all 
the main neuropathological hallmarks of AD, including intracellular 
granular and neurofibrillary structures (Bondareff et al., 1991). MN423 
decorates PHFs isolated with or without pronase treatment in 
immunoelectronmicroscopy studies, binds to the 12 Kdal fragments of the 
core PHFs terminating at Glu391 and does not react with full-length tau 
(Novak et al., 1991). On this basis it was hypothesized that tau is 
endogenously truncated in AD brain at Glu391.  
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Ugolini et al. also investigated the distribution of MN423-
immunoreactivity in AD neurons (Ugolini et al., 1997). Using this antibody 
it was shown intense granular staining inside of neurons that did not exhibit 
any overt neurofibrillary changes, suggesting that the proteolysis of tau 
represent an early pre-tangle stage in the development of neuropathology at 
single cell level. Moreover Ugolini et al., demonstrated a high degree of 
colocalization of MN423 positive neurons with apoptotic neurons 
suggesting a correlation between the truncation of tau at Glu 391 and cell 
death by apoptosis in AD brains. 
 
 
4.1.3 Neuronal Death and Neurodegeneration 
It is well documented that AD is a degenerative disease characterized by 
progressive loss of neurons. In order to investigate which could be the role 
of the proteolysis of tau on the morphological degeneration and profound 
apoptotic cell death of neurons, the ISEL technique was employed in order 
to verify one of the commonly used marker of cell death. 
Apoptosis is a process characterized by cytoplasmic blebbing, cell 
shrinking, neurite degeneration, fragmentation of the nucleus and 
fragmentation of the genomic DNA (Oppenheim, 1991); the ISEL 
technique identify nuclei with fragmented DNA, as DNA fragmentation is 
a commonly accepted marker of cell death. 
MN423/ISEL double labeling studies have demonstrated the presence of 
cleaved tau in AD neurons associated with the expression of markers for 
neuronal death (Ugolini et al., 1997). In that work, only MN423 
immunoreactivity could be tested, but the presence of dying ISEL-positive 
cells that did not shown MN423 immunoreactivity, has suggested that 
intermediate truncated tau fragments could be present inside neurons that 
are not detectable with MN423, that only revealed those fragments whose 
carboxy-terminal residue is Glu391. 
Recently we have demonstrated that the ectopic expression of a tau 
fragment (tau 151-391) induces cell death by apoptosis in COS cells 
(Fasulo et al., 1998), as well as other cell types such as 3T3 fibroblast, SH-
SY5Y neuroblastoma and NT-2 teratocarcinoma cells.  
In order to identify the maximum fragments still endowed with full 
apoptotic properties, we engineered three sets of mutants (C-terminal 
extension, N-terminal extensions, N- and C-terminal truncations of tau 151-
391), and expressed them in COS and NT-2 cells in experiments of 
transient transfection. 
The results of this work in which I have collaborated (Fasulo et al., 2000) 
will be briefly described in the next paragraph. 
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4.2 Results: Tau as substrate and effector of apoptosis 
 
Figure 4.2 illustrates the set of tau constructs, starting at residue 151 
(proline rich-domain) and terminating at residues 274, 305, 336, 368, 391, 
402, 412, 422, 432, 441 (the natural end of tau protein).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.2 The set of tau fragments  
 
 
COS cells were transiently transfected with the tau constructs described in 
Fig.4.2 and analyzed after 48 hours by double labeling with the anti-tau 
monoclonal antibody MN 7.51 and the ISEL procedure for DNA 
fragmentation. 
In the first set of construct (C-terminal extension of tau 151-391) the 
expression of fragments encompassing the proline-rich regions and 
terminating anywhere between residues 391 and 422 induce in a large 
number of cell morphological changes and DNA fragmentation typical of 
apoptosis: 40-45% of transfected cells expressing all fragments terminating 
between amino acids 391 and 422 were apoptotic, with a sharp transition 
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observed upon further extension into the 19 C-terminal residues (Fig. 4.3 
b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4.3 Percentage of cells transfected with tau fragments undergoing 
apoptosis. Percentage of transfected cells were scored for each construct. The 
transfected cells expressing fragments of tau40 and showing DNA fragmentation were 
visualized using a multiple wavelenght filter (Zeiss Filter Set 25), and the percentage of 
apoptotic cells of the total number of transfected cells was determined. The lowest 
percentage of DNA fragmentation was found in cells expressing the dGAE fragment, 
and for this reason this fragment was used as a negative control in all experiments. The 
level of apoptosis induced by dGAE fragment correspond to the backround levels 
induced by negative controls in similar conditions. 
Bars represent standard errors. Asterisk and filled squares over the bars indicate the 
statistical significance with respect to the dGAE and to tau 151-391 respectively 
(p<0.001, except for tau 151-432, p<0.05) for b), and for a) and c) with respect do 
dGAE only (p<0.001, except for tau 151-368, p<0.05). 
In a) N-terminal extension of tau 151-391 fragment and controls. In b) C-terminal 
extension and in c) contribution of the microtubule repeats and proline-rich domain to 
the apoptotic properties of tau fragments. 
Tau-head (tau 1-150): this fragment includes the N-terminal region of tau molecule up 
to Lys150 
Nt-dGAE (tau 1-391): this fragment includes the N-terminal region of tau molecule up 
to Glu391 
P2dGAE (tau 198-391): this fragment includes the second proline rich domain (P2) up 
to Glu391 
 
 
a) b) c) 
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A further mapping of the apoptotic properties of tau fragments (N-terminal 
extension and N- and C-terminal truncation of tau 151-391) revealed that 
unlike the C-terminal extension, the N-terminal extension did not affect the 
apoptotic properties of tau fragments (Fig.4.3 a). 
In other experiments, deletion mutants that are reduced at their N- and C-
termini (Fig.4.3 c) revealed that the N-terminal deletion of the first proline-
rich domain and a reduction at a C-terminus of one microtubule binding 
repeat, lowered the apoptotic capacity of the fragment to a level that is 
intermediate between that of tau 151-391 (maximal apoptotic capacities) 
and of dGAE (minimal apoptotic capacities). 
In this work it was shown that the apoptotic capacity of tau fragments is 
comprised in the set of fragments starting from tau 151-368 up to tau 151-
422.  
A transition point around residue 422 was observed, located around one of 
the three putative caspase-3 cleavage sites (D421), beyond which the 
fragments lose their ability to induce apoptosis. It was also shown that only 
this site, in the C-terminal portion of the molecule, could be effectively 
used by caspase-3 in vitro. 
This work, together with data from an in vitro model of neuronal apoptosis 
(Canu et al., 1998) demonstrates that tau is, at the same time, a substrate 
and an “effector” of apoptosis, suggesting that it could be involved in a 
feed forward mechanism affecting neuronal viability in AD. 
On the basis of the results obtained in this work, the use of intracellular 
antibodies as a tool for in vivo studies and furthermore, as a general 
strategy to interfere with apoptotic stimuli induced by tau fragments, could 
be the final goal of my work. The ability to link the development of the 
intrabody trap technology, that leads to the high throughput isolation of 
knock-out antibodies with a real multifactorial disease, might be the 
demonstration that such system can be readily used to identify novel genes 
involved in the disease area under investigation as “targets” for new drugs 
and/or for gene therapy. 
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Chapter Five: Intrabody trap technology: selection of 
anti human tau intracellular antibodies 
 
5.1 Introduction 
 
To demonstrate whether the yeast antigen-antibody two-hybrid system can 
be feasible also in “real” complex situations, in which the protein under 
investigation has a role in a cascade of events and can be a target itself for 
functional studies and possibly for drug development, we have applied this 
technology or “intrabody trap technology (ITT)” to the isolation of 
intracellular antibodies of tau fragments (see preceding chapter). 
The microtubule-associated protein tau seems to us a good candidate for 
several reasons: 
1. it is the major component of the paired helical filaments (PHFs) 
which are found in the neurofibrillary lesions that correlate with the 
presence of dementia in Alzheimer’s disease 
2. it is known to be involved in microtubule assembly and stabilization 
in neurons but does not appear to be an essential protein, since 
inactivation of its gene by homologous recombination leads to no 
overt phenotype, except a reduction in the number of microtubules in 
some small-caliber axons (Harada et al., 1994) 
3. abnormal posttranslational modifications occur under pathological 
conditions, including hyperphosphorylation (Iqbal et al., 1994), 
glycosylation (Wang et al., 1996), ubiquitination (Bondareff et al., 
1990), glycation (Ko et al., 1999) and truncation (Mena et al., 1996) 
(Fasulo et al., 1996) (Fasulo et al., 1998). Although all these 
abnormalities have been extensively studied under in vitro 
conditions, few examples of in vivo studies were performed so far  
4. the structure and self-assembly of tau protein is still unsolved and the 
mechanisms of PHF formation in vitro is not fully understood 
The efforts performed so far in dissecting all the probable mechanisms 
involved in neurodegeneration that show a possible involvement of tau 
protein as effector of apoptosis (Fasulo et al., 2000) have suggested us to 
apply the ITT on this specific problem in order to obtain intrabodies either 
for studying or, as more ambitious target, for applicative purposes. 
In the next paragraph I will explain all the step performed so far to achieve 
the goal of my project. 
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5.2 Results 
 
5.2.1 Preparation of 151-422 tau fragment bait-antigen 
The first step to achieve in the preparation of an intrabody trap selection 
was the construction of the bait. I have chosen a domain of tau protein, 
including amino acids 151 up to 422 to exclude the higher backgrounds due 
to the transactivation of the reporter construct by the C-terminal domain of 
the protein, that was revealed in pilot studies (data not shown). Moreover, 
fragment 151-421τ display apoptotic properties when expressed in 
mammalian cell and represent therefore a good candidate for isolations of 
intrabodies.  
The constructed bait antigen underwent a series of control-tests as 
described in chapter 2. The transformation of the lexA-151-422τ fusion 
protein alone in L40 yeast cell, or with the VP16* vector did not result in 
activation of the HIS3 nor of the lacZ gene (Fig.5.1, rows 1 and 2 
respectively).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5.1 Transactivation controls for 151-422τ bait. L40 yeast cells were 
transfected with lexA-151-422τ (row1) and cotransformed with lexA-151-422τ and 
VP16* plasmid (row2). Yeast was scored for β-gal activity and streaked and grown on 
his-medium (data not shown). No auto-activation (3 different separated assays were 
performed) of HIS3 and lacZ genes was detected. In row 3 the contransformation of a 
positive control: lexA-AMCVp41+scFvF8-VP16. 
 
 
The absence of background transactivation of the two-reporter genes has 
induced us to proceed in constructing the fusion protein to use for selection 
of the scFv antibody phage library. The purified 151-421 τ fusion with 
maltose binding protein, that was available in the laboratory, (Fig.5.2) was 
lexA-151-422τ 
lexA-151-422τ + VP16 
lexA-AMCVp41 + scFvF8-VP16 
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used for the selection scFv fragments of the human non-immune antibody 
fragments library (Sheets et al., 1998).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5.2 151-421 τ−MBP protein. After extraction, the soluble pool of the fusion 
proteins was affinity chromatographed using amilose resin column. The eluted fractions 
were subjected to a) coomassie SDS-PAGE and b) western blot (after blotting protein 
were detected with the anti-tau mAb 7.51) 
 
 
 
 
5.2.2 Selection of anti -151-421 τ human antibody-fragments from a 
non-immune antibody fragments library 
The purified 151-421 τ−MBP protein was used for the selection of human 
antibody fragments from the Sheets library (Sheets et al., 1998). After the 
151-421 τ−MBP protein was applied to the solid phase, the selection was 
performed by successive rounds of panning, elution, and phage growth, and 
the presence of phage particles with binding specificity for the 151-421 
τ−MBP protein was directly monitored after the second cycle by phage 
ELISA. Enrichment of 151-421 τ -positive phage particles was found after 
two selection rounds, as measured on the single phage clones. The results 
of the screening are reported in Table 5.1. 
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Antigen Round of selection Positive clones 
151-421 τ−MBP 2 77/96 
MBP 2 68/96 
151-421 τ 2 9/96 
 
Table 5.1 Results of the selection second cycle. The number of ELISA 
positive clones and the number of different monoreactive clones is reported 
 
 
 
After two-round of selection using high stringency washes, 77 clones out of 
96 to 151-421 τ−MBP were positive but polyreactive. Only 9.4% of the 
clones were positive and monoreactive (Fig.5.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5.3 ELISA reactivity of the isolated clones against 151-421 τ−MBP 
and MBP. Antigens were coated at 10 µg/ml 
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To test the diversity of this “enriched” library, the isolated scFv were 
fingerprinted by PCR amplification and digestion with BstNI (Fig.5.4).  
 
 
 
 
 
 
 
Fig. 5.4 Fingerprinting patterns of the 96 isolated clones after digestion 
with BstNI. 13 different fingerprints were found, indicating the efficiently 
enrichment of the library due to high stringency conditions. 
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5.2.3 Construction and selection of the activation domain-fusion 
anti-151-421 τ scFv antibody library 
 
 
In order to rescue anti-tau neutralizing antibodies from an intracellularly 
expressed polyclonal repertoire, the bulk DNA encoding for the second 
round polyclonal scFv- anti-151-421τ  fragments was subcloned into the 
VP16 activation domain vector to obtain the library consisting of 6x10
4 
clones. DNA fingerprinting of 20 clones from this library confirmed the 
diversity (data not shown). In order to isolate scFv fragments that 
recognize 151-421τ,  the yeast bait strain was constructed by 
transforming lexA-151-422τ bait into L40 yeast strain. Since pBTM116 
contains TRP1 as a selectable marker, transformants should grow on 
Trp-negative plates and express lexA-151-422τ protein. The yeast bait 
was transformed in large scale with the second round polyclonal scFv-
anti-151-421τ −VP16 library and transformants were selected on –his 
medium for histidine prototropy. After 3 days of incubation at 30°C, 10
5 
yeast transformants were screened by β−gal assay. 90% of the clones 
were identified that interact more strongly (blue-color development that 
take from 5 minutes to 1 hour) with the lexA-151-422τ fusion protein. 
100 blue colonies were grown, DNA encoding for the scFv-anti-151-
421τ−VP16 was isolated and the fingerprint of BstNI digestion products 
analyzed (Fig.5.5). 
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Fig.5.5 Fingerprinting patterns of the 100 isolated clones after 
digestion with BstNI. DNA fingerprinting analysis of the isolated clones were 
confirmed by other gels: clones 37 and 85 that cannot find in this gel are visible in other 
gels. The comparison of different gels revealed 5 different fingerprintings (Fig.5.6) 
 86 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5.6 Fingerprinting analysis of the 5 different clones. The % reported 
indicates the frequency at which each scFv fragment is represented in the input second 
cycle library. Single clones may be spurious false positive, as confirmed by other 
analysis (see Fig.5.7). 
 
The analysis of the hundred fingerprints revealed 5 different patterns 
representing 5 independent scFv-fusions to VP16 acidic activation domain. 
The percentage of scFv fragments that have the same fingerprint in the 
input library is high for type 2 and very low for the others, indicating that 
the in vitro enrichment was very stringent for the other scFv types. To 
control for false positives the five independent clones were further re-tested 
in a two-hybrid assay with the lexA-151-422τ bait. In this screen, only 3 
scFv transformants containing the bait plasmid were able to transactivate 
the HIS3 and the lacZ genes (Fig.5.7). These clones were sequenced to 
confirm the diversity and to verify the correct in-frame fusion (data not 
shown). 
In general, interactions that have affinity tighter than a Kd value of 10
-6
 will 
be detected by a two-hybrid system. Although there may exist a weak 
positive correlation between apparent strength of binding and biological 
significance, many apparently weak interactions are real while some strong 
ones are not. To be sure that antigen-antibody interactions chosen by the 
ITT showed a biological significance, scFv fragments that were weak and 
2 14 37 52 85 
bp 
310 
281 
118 
75% 16% 1% 1% 7% 
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strong positive were re-tested in a two-hybrid assay and the same antibody-
antigen pairs were further verified by a different biochemical technique 
(see paragraph 5.2.5), while others that did not interact after a second two-
hybrid screening were not chosen for use in subsequent verifications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5.7 Interaction of lexA-151-422τ bait with 5 independent scFv-
fusions to VP16 AD-domain. L40 yeast strain was cotransformed with lexA-151-
422τ bait and the panel of the isolated scFv-VP16 plasmids. Only scFv2, scFv14 and 
scFv52 were able to transactivate HIS3 and lacZ genes (row1, 2 and 4) while scFv37 
and scFv85 were not (row 3 and 5). scFvF8-VP16+lexA-AMCVp41 were used as 
positive control (row6). 
 
 
 
The scFvs-anti-151-421τ protein were also tested by cotransfection with 
other baits encoding lexA DNA-binding domain alone or as fusion with 
lamin, and growth was detected in his- medium (data not shown). β-gal and 
HIS3 activations were not observed after three days of incubation at 30°C, 
indicating that these scFv are able to specifically interact only with their 
corresponding 151-421τ antigen under the intracellular conditions of this 
assay. 
lexA-151-422τ + scFv2-VP16 
lexA-151-422τ + scFv14-VP16 
lexA-151-422τ + scFv37-VP16 
lexA-151-422τ + scFv52-VP16 
lexA-151-422τ + scFv85-VP16 
lexA-AMCVp41 + scFvF8-VP16 
+ 
+ 
+ 
- 
- 
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5.2.4 Is the in vivo selection needed? 
In order to test the input library that was used for the ITT selection for 
isolating intrabodies without any in vivo selection scheme, four ELISA 
positive anti-151-421τ protein after the second cycle of in vitro selection 
were coexpressed with lexA-151-421τ bait as scFv-VP16 fusion proteins in 
yeast.  
No transactivation of HIS3 and β-gal genes were observed after three days 
of incubation at 30°C (data not shown), confirming that there is a need for 
an in vivo selection procedure for the isolation of scFvs able to display 
intracellular antigen-antibody interactions.  
 
 
 
5.2.5 scFv-anti-151-421τ protein in vitro characterization  
To determine the binding activity of the three scFv fragments, the scFvs-
anti-151-421τ protein were cloned into prokaryotic phagemid expression 
vector pUC119CAT. This vector displays the expressed scFv on the surface 
of the filamentous M13 phage by fusion with the gene III minor coat 
protein (g3p) that is required for host infection (McCafferty et al., 1990). 
Following isopropyl-thiogalactoside (IPTG) induction, soluble scFv were 
expressed in the periplasmic space of amber-suppressor bacteria (HB2151 
E.coli strain) recognizing an amber mutation interposed between genes 
encoding the antibody fragment and the coat protein (Hoogenboom et al., 
1991). To allow the immunodetection of the soluble scFv, the myc tag 
peptide is fused in frame at the C-terminus of the Vk domain. Preparation 
of pure scFv-anti-151-421τ protein from E.coli periplasm was achieved by 
affinity chromatography using the His tag.  
Analysis by SDS-PAGE (coomassie staining and western blot) revealed a 
band at the expected size (30 kDal), with great purity after purification. The 
average yield of immunopurification from the periplasmic fractions was 
300-900µg of scFv per liter of bacterial culture. 
All three scFv fragments were tested in ELISA against the protein used for 
the selection in vitro (MBP-151-421τ), the deletion mutant used for the 
selection in vivo (MBP-151-422τ), the relative full-length protein tau and 
the MBP. All the soluble scFv fragments were specific for tau and for its 
deletion mutants and did not recognized maltose-binding protein (Fig.5.8). 
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Fig.5.8 Reactivity of the isolated clones against tau protein, tau deletion 
mutants and MBP. The ELISA signal was measure at O.D. 450. 
 
 
 
 
5.2.5.1 Analytical gel filtration 
ScFv fragments often show a propensity to aggregate in to dimers or 
multimers. 
After purification by affinity chromatography using His tag, the three scFv 
fragments were subjected to analytical gel filtration in order to isolate the 
monomeric form and to assess the gel filtration profile of the single chain 
antibody fragments. All the purified scFvs showed a single peak elution 
profile corresponding to the monomeric form of the scFv fragments. More 
than 90% of the protein was monomeric. (Fig.5.9). Therefore, these gel 
filtration data reflect the low aggregating behavior of the scFv fragments 
indicating the capability of these scFvs of maintaining the ability of 
independent structure formation also under in vitro conditions. 
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Fig.5.9 Analytical gel filtration. The amount of monomeric protein was 
quantified by integrating the peak representing monomeric scFv fragments, which was 
eluted from a Superdex-75 analytical gel filtration column. Elution volumes and 
molecular mass marker proteins are indicated. As a representative example, the 
analytical gel filtration chromatogram of scFvαD11 shows the amount of dimeric and 
aggregated species that were eluted at about 10.5 ml. The amount of remaining 
monomeric species decreased with increasing incubation time (data not shown). 
 
 
 
5.2.5.2 Competition ELISA 
In order to measure the affinity constants of the isolated scFv towards the 
corresponding antigens, equilibrium saturation analysis was performed by 
competition ELISA (Fig.5.10). After incubation of monomeric scFv 
fragments with the antigen, the concentration of free antibody was 
determined by indirect ELISA. The concentration of the scFv antibody was 
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chosen to be close to the estimated value of the dissociation constant. ScFv 
fragments supernatants were titrated with known antigen concentrations. 
The calibration curves shown in Fig. 5.10 demonstrate that for scFv2 and 
scFv14, the absorbance versus the initial concentration of antibody is linear 
in a range of concentration between 0.08-0.02µg/ml and 0.08-0.01µg/ml 
for scFv2 and scFv14 respectively. It was not possible to obtain linear 
calibration curve for scFv52 under the same experimental conditions 
probably because of the lower affinity of the interaction. A second possible 
explanation for this is that the scFv52 was not able to recognize the antigen 
in solution because of a hidden epitope due to possible interaction between 
the bound antigen and the one in solution. 
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Fig.5.10 a) Calibration curves of the binding of scFv2 and scFv14. The 
concentration range of purified 422MBP was 100nM-1µM. Each assay was analyzed in 
triplicate. This figure shows that scFv2 and scFv14 have linear relation between 
absorbance and dilution in a wide range of antigen concentration, while scFv52 fails to 
display such a behavior. 
 
The dissociation constant for scFv2 and scFv14 were determined from the 
corresponding equilibrium binding curves shown in Fig. 5.10 b) and c), 
taking into account the half of the maximum value of absorbance at 
O.D.450 of free antibody, yielding a Kd of 357 nM and of 143 nM for 
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Fig.510 b) and c): Kd was derived at semisaturation of free antibody by plotting the 
absorbance on the ordinate versus the concentration of free ligand on the abscissa. 
 
 
 
 
b) 
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5.2.6 In vivo expression of anti-tau scFv intrabodies: intracellular 
retargeting of cotransfected 151-422τ by the scFv intrabodies 
Using transient transfection analysis, the effect of the anti-tau scFv 
fragments on 151-422τ  fragment was studied. Cellular expression of the 
anti-tau scFv intracellular antibodies was first analyzed by 
immunofluorescence microscopy of transiently transfected COS and CHO 
cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5.11 Immunofluorescence microscopy of the anti-151-
422τ  scFv fragments transiently transfected in COS cells. Cyto-scFv2, 
cyto-scFv14 and cyto-scFv52 were visualized under a fluorescence microscope; cells 
were reacted with the anti-myc tag antibody 9E10, followed by incubation with an anti-
FITC-conjugated anti-mouse (Vector).  
 
 
 
As demonstrated in Fig.5.11, the anti-tau scFv fragments shown a diffuse 
intracellular staining typical of soluble cytoplasmic proteins, confirm the 
good solubility properties of the isolated scFv fragments. 
In order to demonstrate the interaction of antigen-antibody in mammalian 
cells, retargeting was thought to be one possibility. The effect of the three-
scFv fragments on cotransfected 151-422τ antigen was evaluated in terms 
of their ability to retarget 151-422τ to a different subcellular compartment 
in an antibody-depending way. In order to do this, the three scFv fragments 
were cloned in mammalian expression vector containing a myc tag (Persic 
et al., 1997) and a nuclear localization signal and individually coexpressed 
in CHO cells with the cytoplasmic fragment 151-422τ (Fasulo et al., 2000). 
scFv2 scFv14 scFv52 
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The soluble scFvR4 (Martineau et al., 1998) was used as a non relevant 
scFv control. 
After 36-40 h post-transfection, the cell were fixed, permeabilized, and 
stained with the anti-myc rabbit polyclonal antibody and with the mouse 
anti tau 7.51. Using immunofluorescence microscopy, the subcellular 
localization of the 151-422τ antigen and its corresponding scFv fragment 
were visualized (Fig.5.12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5.12 Dual immunofluorescence analysis of retargeting of 151-
422τ antigen in the presence of different scFv fragments. Row1: 
cytoplasmic (cyto) 151-422τ antigen (a), (nuclear targeted, nls) nls-scFv2 (b), nls-
scFv14 (c), nls-scFv52 (d) and nls-scFvR4 control antibody (e). Row2: coexpression of 
cyto-151-422τ antigen with nls-scFv2 (f), with nls-scFv14 (g), with nls-scFv52 (h) and 
with nls-scFvR4 (i). All the nls-scFv fragments were FITC-stained while the 151-
422τ antigen was Texas-RED-stained. Transfected cells were visualized using a 
multiple wavelengths filter (Zeiss Filter Set 25). Only the cotransfected cells with cyto-
151-422τ antigen and with nls-scFvR4 display the double different labeling which 
correspond to the proper targeting locations: green nucleus for the nls-scFvR4 and red 
cytoplasm for the cyto-tau fragment antigen. All the nls-anti-151-422τ antigen scFv 
fragments colocalized in the nucleus with the retargeted cyto-151-422τ antigen (red 
nucleus). The arrow in f) indicate a nuclear staining for the retargeted cyto-151-
422τ antigen. 
 
 
a 
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Fig.5.12 shows that 151-422τ was a cytoplasmic protein in CHO cells 
when transfected alone (row1, a) or when it was cotransfected with the 
non-relevant nuclear-scFvR4 (row2, i). In contrast, nuclear staining was 
observed when scFv2 (row2, f), scFv14 (row2, g) and scFv52 (row2, h) 
were coexpressed. The retargeting of 151-422τ was due to specific 
interactions between 151-422τ antigen and the anti-151-422τ single chain 
antibody fragments. This was confirmed by the coexpression of the 
irrelevant nuclear-scFvR4, which failed to retarget the 151-422τ antigen 
under the same intracellular expression conditions. This result demonstrates 
that a specific antigen-antibody interaction is required for retargeting. 
This quality observation was quantified in the cell populations (n=100 
counted cells for each experiment). The retargeting was evaluated as the 
ability of the nuclear scFv fragments to colocalize tau in the nucleus or as 
the ability of cytoplasmic tau to retain the nuclear scFv fragment in the 
cytoplasm. According to both criteria, antigen-antibody interactions were 
shown. 
The effect on re-directing 151-422τ  to the nucleus  was less prominent that 
the retargeting of nuclear scFv fragments into the cytoplasm (Fig.5.13) but 
the overall efficiency of the anti-tau scFv antibody fragments to bind the 
antigen was absolutely clear with respect to the control scFvR4 to occur.  
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Fig.5.13 Effect on retargeting of 151-
422τ   in CHO cells by scFv2, scFv14, 
scFv52 and scFvR4.  
1) τ nuclear and cytoplasmic 
scFv nuclear and cytoplasmic 
2) τ nuclear 
scFv nuclear 
no staining of the cytoplasm 
3) τ cytoplasmic 
scFv cytoplasmic 
no staining of the nucleus 
4) τ cytoplasmic 
scFv nuclear 
Pattern 1), 2) and 3) are indicative of an 
interaction between τ and scFv. 
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5.2.7 Selection from a scFv phage display library after one round of 
antigen panning 
The affinity of the antibodies isolated using a conventional phage display 
library, is proportional to the initial size of the library used for the 
selection. The use of larger libraries has become an important goal in phage 
display, and in theory also in ITT the same fundamental consideration may 
be applied with the addition that this procedure may rescue scFv fragments 
not only on the basis of best affinity in vivo but also for best solubility. 
One of the most important limitations using this technology is that the 
efficiency of transformation of yeast cell does not exceed 10
6
/µg DNA. 
This important consideration has suggested us to clone, as first attempt, an 
enriched anti-151-421τ   polyclonal phage population, to overcome this 
problem. The results showed so far, have demonstrated that it is possible to 
rescue functional and soluble antibody fragments that bind their antigen 
under intracellular expression conditions, after two cycles of antigen 
panning in vitro. In order to detect the sensibility of the ITT versus the 
diversity of the library, the first panning cycle of the polyclonal anti-151-
421τ DNA was cloned as fusion library with the activation domain of the 
VP16 vector. 
The library consisted of 2.2x10
6
 clones. DNA fingerprinting of 96 clones 
confirmed the diversity of this library (data not shown).  
The fist cycle anti-151-421τ -VP16  DNA was cotransformed in lexA-151-
422τ L40 yeast strain as described before. 
After 3 days of incubation at 30°C, 10
4 
yeast transformants were screened 
by β-gal assay and 50 blue colonies were subjected to PCR fingerprinting. 
11 different fingerprints were detected in which we were able to rescue also 
identical fingerprinting to those of scFv2, scFv14 and scFv52 (data not 
shown). Six blue colonies with different fingerprinting were picked into 
liquid culture and plasmid DNA encoding for scFv-VP16 transactivation 
domain fusion was segregated. Yeast L40 was then cotransformed with the 
lexA-151-422τ DNA-binding bait clone together with each one of the 
isolated scFv-VP16 plasmids. 4 out of the original 6 clones grew on –his 
plates and showed a positive interaction when β-gal assay was performed 
(Fig.5.14), indicating that selection of anti-151-421τ scFv fragments from a 
library panned ones on antigen is indeed feasible and can lead to the rescue 
of more candidates for intracellular expression. 
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Fig.5.14 Intracellular interaction of scFvA2 (row1), scFvA3 (row2), 
scFvA6 (row3) and scFvC12 (row4) with target antigen lexA-151-
422τ in L40 yeast cells. Cotransformed yeasts were streaked and grow on his- 
medium and scored for β-gal activity. β-gal activity was observed in each His+ clones. 
 
 
5.2.8 In vivo epitope mapping (IVEM) 
Epitope mapping is an important part of the characterization of an antigen. 
For research, diagnostic, and therapy it is desirable to have antibodies that 
bind to a given epitope of an antigen. Many different approaches have been 
used, but all explored the possibility to map the epitope in vitro. Epitope 
mapping is using a very laborious procedure. In general the most useful 
technique in determining the epitopes recognized by a number of 
antibodies is the use of peptide, which can be displayed as peptide-phage 
library or used as synthetic products (Bradbury & Cattaneo, 1995). This 
strategy is very general, and sometimes the peptide motifs have no 
resemblance to the primary sequence of the protein antigen and this 
indicates that the epitope that is recognized by the antibody is a 
discontinuous or conformational epitope.  
The ability of the two-hybrid system to display the in vivo conformation of 
the protein and to detect conformational changes in a given protein, has 
induced us to explore the ability of this system to determine the epitopes 
recognized by the three isolated scFv fragments. To perform this, deletion 
mutants of the protein tau were fused in frame to lexA binding domain. The 
set of fragments included (see also chapter four, fig. 4.2): 
• Tau 151-274: this fragment includes the proline rich domain and the 
R1 repeat 
• Tau 151-305: this fragment includes the proline rich domain and the 
R1-R2 repeats 
lexA-151-422τ + scFvA2-VP16 
lexA-151-422τ + scFvA3-VP16 
lexA-151-422τ + scFvA6-VP16 
lexA-151-422τ + scFvC12-VP16 
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• Tau 151-336: this fragment includes the proline rich domain and the 
R1-R2-R3 repeats 
• Tau 151-368: this fragment includes the proline rich domain and the 
R1-R2-R3-R4 repeats 
• Tau 151-391: this fragment includes the proline rich domain and the 
R1-R2-R3-R4 repeats extended up to Glu 391  
• Tau 151-402: this fragment includes the proline rich domain and all 
the repeats extended up to Asp 402 
• Tau 151-412: this fragment includes the proline rich domain and all 
the repeats extended up to Ser 412 
• Tau 151-422: this fragment includes the proline rich domain and all 
the repeats extended up to Ser 422 
• dGAE: is one of the AD PHF core fragments (Wischik et al., 1988b) 
 
The expression level of lexA-fusion bait proteins was assessed by western 
blot analysis using the polyclonal antibody anti-lexA protein (Fig.5.15 a), 
mAb Tau-1 (Roche) (Fig. 5.15 b) and mAb 7.51 (Fig.5.15 c) (Evan et al., 
1985). The specificity of the three different scFv fragments against the 
panel of antigen baits is illustrated in Fig.5.16 and summarized in Table 
5.2. 
 
 
 
 
 
Antigen 
151-
274 
151-
305 
151-
336 
151-
368 
151-
391 
151-
402 
151-
412 
151-
422 
dGAE 
scFv2 - - - - - - + + - 
scFv14 - - - - + + + + + 
scFv52 - - - - - - + + - 
 
 
 
 
Table 5.2 Specificities of the scFv2, scFv14 and scFv52. Binding was 
determined by ITT to a panel of deletion mutants of tau protein by transactivation of 
HIS3 and lacZ genes.  
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Fig.5.15 Western blot ananlysis of lexA-deletion mutants of tau fusion 
proteins. a) the proteins were revealed by using a polyclonal antibody anti-lexA, b) 
the proteins were revealed by using a generic anti-tau monoclonal antibody Tau-1, c) 
the proteins were revealed by using another generic anti-tau monoclonal antibody 7.51. 
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Fig.5.16 Epitope mapping of scFv2, scFv14 and scFv52.  Growth (-his 
plates) and β-gal phenotypes conferred by the set of fragments of tau 
interacting with the three-scFv fragments.  
151-274τ+scFv2 
151-274τ+scFv14 
151-274τ+scFv52 
151-305τ+scFv2 
151-305τ+scFv14 
151-305τ+scFv52 
151-336τ+scFv2 
151-336τ+scFv14 
151-336τ+scFv52 
151-368τ+scFv2 
151-368τ+scFv14 
151-368τ+scFv52 
151-391τ+scFv2 
151-391τ+scFv14 
151-391τ+scFv52 
151-402τ+scFv2 
151-402τ+scFv14 
151-402τ+scFv52 
151-412τ+scFv2 
151-412τ+scFv14 
151-412τ+scFv52 
151-422τ+scFv2 
151-422τ+scFv14 
151-422τ+scFv52 
dGAE+scFv
2 dGAE+scFv14 
dGAE+scFv52 
-HIS β-gal 
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This new way to map the epitope of given intracellular antibodies in vivo 
(in vivo epitope mapping, IVEM), is a valid alternative to laborious and 
expensive approaches that will always reveal the in vitro and not the in vivo 
properties of an intrabody. The simplicity of this approach should also be 
extended to a high throughput screening, were interesting intrabody 
specificities may also be obtained using this system. 
 
 
 
5.3 Discussion 
 
 
5.3.1 Intabody trap technology: a new selection procedure to 
facilitate protein knock-out at a genomic scale 
The complexity of the genome of many organisms, and in particular of 
mammalian genomes renders the functional understanding of a new protein 
superficial if it is examined only with experimental genomic technologies. 
The efforts to trace the intricate connections and activities of proteins have 
induced many laboratories to develop even more sophisticated technologies 
with the whole tools of cell and molecular biology, genetics, biochemistry 
and structural analysis. One of the strategies adopted to generate protein 
linkage maps of large networks of interacting proteins is the two-hybrid 
system. This approach is having a strong impact in functional genomics 
where proteins of unknown function, predicted from genomic sequences, 
generate complex relationships and connections among the elements, 
sometimes previously suspected or not. 
In the last decade yeast two-hybrid system have been used to isolate 
interactors of many proteins of interest. The idea to use the two-hybrid 
system to isolate intracellular antibody-antigen pairs arises from the 
modular nature of the system itself and from the fact that the interaction 
occurs under the reducing condition of the cell cytoplasm and the nucleus. 
Intracellular expression in mammalian cell has extensively demonstrated 
that neutralizing antibodies can confer new phenotypic traits upon 
interactions, but the bottleneck of using directly specific antibodies derived 
from monoclonals or from phage display libraries, is due to the difficulty of 
finding antibody that respect the requirement for good intracellular 
performance, that are high solubility, high stability and good affinity.  
The study performed so far in the field of antigen-antibody two-hybrid 
system has demonstrated that this approach is not only feasible to detect 
this kind of interaction but provide a ‘proof of principle’ for the concept of 
selection of intracellular libraries, whereby a polyclonal population of 
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antibody fragments can be intracellularly expressed and can be an 
unlimited source of  “high affinity intra-binders”.  
 
 
5.3.2 The choice of tau protein as “target antigen” 
To design a suitable selection scheme using the “intrabody trap 
technology”, the case of a multifactorial disease was evaluated. 
Alzheimer’s disease is one of the most common causes of late-life 
intellectual impairment in countries that have achieved life expectancies 
above 70 years. In contrast with other unsolved disease of the human brain, 
Alzheimer’s disease presents features that make it particularly amenable to 
studies of pathogenesis at the molecular level. Accumulation in the brain of 
the classical hallmarks of the disease, neurofibrillary tangles and senile 
plaques are the defining feature of AD. It is still not known how the 
formation of these pathological structures occurs and how they contribute 
to the gradual decrease in the numbers of synapses and neurons that seems 
to be of particular clinical importance.  
The abundance of neurofibrillary tangle seems to be more closely related to 
the extent of neuronal loss found in AD brain; furthermore the tangle 
formation seems to be a late event and presumably represent a final 
pathway towards neuronal death in subset of neurons (Morishima-
Kawashima et al., 1995). 
The evidence that proteins that are involved in PHF formation should be 
one of the key events that leads to neurodegeneration has lead us to focus 
our attention on one of the main component of this abnormal deposit. 
The principal component of PHF, which are the main constituent of 
neurofibrillary tangles, is the protein tau. 
Understanding of the cellular and molecular biology of the processes in 
which tau protein is involved is an essential prerequisite for the 
development of an early diagnostic assay and drugs capable of preventing 
steps leading to this neurodegenerative disease.  
Attempts for therapeutic intervention need to focus on the primary defect 
which tau and other proteins are responsible for initiating the neuronal 
degeneration and the application of antibodies to use in in vivo experiments 
should greatly facilitate the understanding of the molecular processes 
which tau protein is involved. 
 
 
5.3.3 From gene to antibody bypassing proteins 
One of the prerequisite of the ITT is that the entire selection scheme passes 
through gene to the antibody without a necessary and obligatory handling 
of the protein. 
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This may have great advantages because handling of DNA is much more 
cost-effective and simple than handling of protein. 
The application of the two-hybrid system on a large scale has increasingly 
broadened the application of this technique in detecting protein pairs, 
complexes and also DNA-protein pairs. The use of this system is becoming 
even more versatile. The application of the ITT in the genome sequencing 
projects may facilitates the research of individual gene functions but also 
may provide a generic tool for many functional genomic characterizations 
as, for example, protein localization, protein-protein interaction maps and 
gene knock-out. 
Following the results obtained with the model selection experiment the 
possibility of carrying out library search with ITT was implicit in the 
original idea. To perform such experiment several schemes on the 
methodologies were becoming available in order to facilitated spread of 
this technology.  
The first requirement to develop ITT selection scheme was to solve the 
problem of the size of the input scFv library that, in our case (Sheets et al., 
1998) is in the order of 10
9
 different clones. To deal with the very low 
efficiency of transformation of the yeast, that cannot exceed 10
6
/µg of 
DNA, a need of a preselection step in order to achieve the repertoire size of 
10
4
-10
6 
was evaluated. In general, the best approach to enrich a library is to 
perform affinity purification on antigen column. 
The selection scheme for the isolation of intracellular scFv was initially 
tested using a polyclonal anti-151-421τ population from the second cycle 
of selection and successively a polyclonal anti-151-421τ population from 
the first cycle of selection.  
The diversity of the polyclonal anti-151-421τ population from the second 
cycle of selection was evaluated to be around 13% (i.e. 13 different 
fingerprinting pattern were found out of a random selection of 100 clones). 
The number of specific anti-151-421τ scFv fragments was evaluated to be 
in the order of 10% after the selection of the second cycle. Furthermore, the 
percentages of different scFvs achieved after fingerprinting screening of 
100 clones was only 5% (i.e. 5 different fingerprinting pattern of scFv in 
the two-hybrid selected library) and among these only 3 were positive after 
a second two-hybrid screening. The analysis of the fingerprinting pattern 
obtained from the isolated two-hybrid positive scFv fragments has 
indicated that two putative positive binders could be rescued analyzing 100 
different scFv positive anti-151-421τ scFv fragments after the phage-
ELISA. These scFvs (scFv2 and scFv52) were present at higher frequency 
in the polyclonal population (20% for scFv2 and 2% for scFv52). It was 
impossible to rescue any scFv14 fingerprinting pattern in the same 
polyclonal population, and this indicates that ITT is able to detect rare scFv 
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fragments with higher sensitivity, lower time-consuming selections 
schemes than phage display technology with the advantage of rescuing 
directly for in vivo specificities. 
To stress the importance of the in vivo selection scheme, four different anti-
151-421τ scFv fragments selected with antigen from phage display library 
were analyzed by expression in two-hybrid format. None of these exhibited 
binding to antigen in the cytoplasm of the yeast cell, indicating that an 
effective selection scheme for intracellular antigen-antibody interactions is 
required. 
The finding obtained so far has indicated that the selective pressure arises 
from the in vitro enrichment during phage library panning cycle may lead 
to a loss of variability of the polyclonal repertoire. To overcome this 
problem a first cycle of selection on 151-421τ antigen was investigated. 
The results obtained has indicated that this polyclonal population of anti-
151-421τ scFv fragments is compatible with selection schemes in yeast 
two-hybrid format, not limiting the sensitivity of the assay to screen all 
possible candidates. In fact, the polyclonal repertoire was restricted enough 
to deal with yeast transformation but the diversity was still high enough 
(90% of the clones undergone to PCR-fingerprinting analysis had different 
pattern, data not shown) to permit selection of 4 new positive scFv after 
screening of only 6 different blue colonies. The diversity of the library after 
two-hybrid screening was restricted to 20% of the total. This result 
confirmed that the system is able to fish out many new intracellular 
candidates from the high variability of the intracellular scFv repertoire, 
indicating that selection of even more different specificity could be rescued 
by scaling up the number of the transformed yeast colonies. 
 
 
5.3.4 Solubility and affinity of the selected anti-151-422τ scFv 
fragments 
In the present study we have also investigated the interplay between in 
vitro affinity, solubility and the performance of in vivo expressed scFv 
intrabodies. 
Anti-151-422τ scFv fragments have essentially very similar affinity as 
demonstrated by competition ELISA and all scFv were almost exclusively 
in the monomeric format, showing a small “diabody” peak. All the selected 
scFv fragments were able to bind in vitro not only the deletion mutant 151-
421τ used in preselection screening but also the deletion mutant 151-
422τ used for in vivo selection. Furthermore, all the scFv recognize also the 
full-length protein, but no irrelevant proteins were recognized by the scFvs 
either in vivo or in vitro. This result indicates that antibodies obtained by 
ITT follow all the criteria of a good monoreactive and highly specific best-
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performing intrabody without the need of further protein engineering to 
improve stability and affinity of the isolated proteins. 
 
5.3.5 Efficiency of intracellular antibody-mediated nuclear retargeting 
of 151-422τ protein 
The intracellularly expressed scFv fragments, which bind in two-hybrid 
format with 151-422τ protein, is demonstrated in this study to have specific 
properties toward redirection of the localization of the antigen to a 
particular subcellular compartment. 
The expression of several scFv fragments show distinct propensity to 
aggregate, when expressed in the cytoplasm of mammalian cells, 
depending on the overall expression levels (Persic et al., 1997). Their 
performance depends primarily on their amino acid sequence, in an 
unpredictable way (Cattaneo & Biocca, 1999).  
The phenomenon of the aggregation occurs naturally during maturation of 
newly synthesized native proteins and represents an off-pathway of the 
normal folding process (Wetzel, 1994). 
In order to evaluate this possibility, the expression of the three anti-151-
422τ protein was compared in immunofluorescence studies. All the scFvs 
showed a diffuse intracellular staining typical of soluble cytoplasmic 
proteins. The same homogeneous staining was exhibited when scFv 
fragments were directed by means of an intracellular-trafficking signal, to 
the nucleus. 
The effects of the anti-151-422τ protein on cotransfected 151-422τ protein 
were evaluated in terms of their ability to retarget 151-422τ protein to a 
different subcellular compartment. 
All the three scFv fragments were able to retarget 151-422τ protein to the 
nucleus (the irrelevant scFvR4 did not exert the same capabilities), 
although the efficiency was sometimes variable due to the property of 
aggregation of the antigen-antibody complex. In fact, when anti tau 
antibodies were interacting in vivo with the tau antigen, it was shown that 
the latter was able to divert them from its normal location and to change 
their solubility state. This fact was less evident when the expressions of the 
scFv fragments were higher then the expression of tau antigen. Modulation 
of the expression of the antigen or expression of the antigen-antibody pairs 
in a dicistronic vector, may avoid this problem. 
These findings demonstrate that, despite the reduced conditions of the 
intracellular environments, these scFv were efficiently expressed in the 
cytoplasm and in the nucleus of mammalian cells, and that they maintain 
the same binding capabilities showed in the yeast cells, confirming that ITT 
is a feasible technique to allow the isolation of intrabodies without a need 
for further scFv engineering for increased folding stability. 
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5.3.6 Epitope mapping 
In the present study the design of a suitable selection scheme that should 
allow the selection of antibodies against known or unknown epitopes was 
presented.  
Moreover, fine specificity of the anti-tau scFv fragments was investigated 
by testing the recognition of several deletion mutants of tau protein by 
using ITT. The originality of this technique is that the epitope mappings 
were performed in vivo without the use of laborious, time-consuming and 
expensive peptide productions and with the same accuracy of the classical 
methods.  
These findings should greatly accelerate the detection of critical epitopes in 
high throughput screening, were identifying functional sites is correlated 
with how the protein actually works. 
Moreover, the functional analysis of proteins that are multifunctional may 
also be remarkably accelerated by the use of a panel of intrabodies that 
could be rescued after an ITT selection schemes.  
 
 
5.3.7 Possible exploitation of the ITT in a genome-wide study 
Genome sequencing projects are predicting large numbers of novel 
proteins, whose interactions with other proteins must mediate the function 
of cellular processes. To analyze these networks, several techniques should 
be used on a genome-wide scale. Among these the two-hybrid system 
seems to be the most rapid and sensitive, yielding the DNA sequences 
encoding proteins to interact and allowing many searches to be conducted 
simultaneously (Bartel et al., 1996). 
The data generated from the protein interaction analysis offer insight into 
the possible biological roles of genes with unknown functions by 
connecting them to other characterized proteins, or can provide novel 
interactions between proteins that are known to be involved in a common 
biological process, or can assign novel functions to some previously 
characterized proteins. Recent papers (Bartel et al., 1996) (Fromont-Racine 
et al., 1997) (Walhout et al., 2000) (Flajolet et al., 2000) (McCraith et al., 
2000) (Uetz et al., 2000) (Ito et al., 2000) have demonstrated the success 
and the widespread applications of the two-hybrid system in practical 
approaches for the identification of interacting partners by screening 
methods on a genome-wide scale. 
One approach that can be used to understand protein function is to disrupt 
and/or manipulate gene expression. The coming era will require several 
generic reagents and methods for the characterization of gene functions 
(Lander, 1996). ITT can find exciting applications in conjunction with 
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functional genomics programs, in particular with programs aimed at 
systematically studying the protein network of a cell (see Fig.5.17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5.17 Protein interaction map. An example of a functional analysis of a 
genomic library screening in which for each bait are selected a limited set of interacting 
preys that are classified in categories of distinct heuristic values (Fromont-Racine et al., 
1997). The use of intrabodies to systematically distrupt this kind of networks can get 
closer to the understanding of function. As shown in the figure scFvs can interfere or 
block interactions between a known gene product (A) and several unknown genes (E, F, 
G, H, I, J). scFvs can block protein interactions at the level of the known protein (red 
spot on A) or at several level of the unknown gene products (red spots on E, F, G, H, I, J 
respectively). The distruption of such interactions can perturb many other linkage in the 
network under investigation helping the comprehension of the associations formed 
during a high throughput two-hybrid screens.  
 
Despite the need for comprehensive studies on in vivo protein-protein 
interactions, the knock-out technologies developed so far are not so general 
to be applied in a genome-wide studies, althought some studies using 
combinatorial protein reagents (i.e. aptamers and phage display 
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technology) have demonstrated that proteins could be the latest 
breakthroughs to probe regulatory networks (Geyer et al., 1999) (Colas, 
2000) (Blum et al., 2000).  
Antibodies are the most popular class of molecules providing molecular 
recognition. Their usual format for their application in a high-troughput 
screening is that of small binding units, for instance scFv fragments. The 
intracellular antibody strategy increases the spectrum of the antigens which 
are accesible to functional studies. Recent advances in the field of 
intracelluar expression of antibodies have demonstrated that the use of 
molecular-repertoire technology and genetic screens under conditions of 
cytoplasmic expression should allow the selection of new antibody 
specificities or antibody frameworks more suitable for the particular 
expression condition of interest (Worn & Pluckthun, 1999) (Worn & 
Pluckthun, 1998) (Visintin et al., 1999). 
Recombinant antibody fragments expressed in the cytoplasm of the cells 
have considerable practical potential. However in the reducing 
environments of the cytoplasm, the intradomain disulphide bonds are not 
formed and fragments are unstable and expressed in low yields. To 
overcome these limitations several strategies were applied (Martineau et 
al., 1998) (Visintin et al., 1999) and we believe that the use of selection 
strategies in combination with the use of libraries that are constructed on 
very stable frameworks should be more effective and should improve 
expression and stability of scFv fragments. 
The results obtained during these years have indicated quite clearly what 
are the limitations of the use of ectopic expression of antibodies. There is 
considerable room for improvements, however, in particular as far as the 
optimization of promoters, choice of new tags (i.e. GFP proteins), looking 
for new targeting signals. 
None of the other approaches to gene- or protein- knock-out produce an 
effect that is general and reproducible from line to line as the ectopic 
expression of antibodies. Moreover, the mechanism by which antibodies 
prevent gene expression is quite clearly understood while this is not true for 
other techniques such as RNAi and antisense RNA. The dramatic recent 
progress in uncovering the gene-specific silencing in a number of 
organisms may be an additional challenge to allow high-throughput sample 
analysis in conjunction with other better characterized techniques. 
The expression of antibodies to dissect signal transduction pathways should 
have several advantages over other methods and may lead to a better 
understanding of the regulatory events involved in normal and disease 
processes and offer a systematic approach for searching for effective 
targets for drug discovery and diagnostics. 
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Conclusions 
 
The present study describes the development of a new technology, which is 
capable of selecting antibody-fragments under intracellular expression 
conditions. This technology involves the use of the yeast two-hybrid 
approach in which a scFv linked to a transcriptional transactivation domain 
can interact with a target antigen linked to a DNA-binding domain, and 
thereby activate a reporter gene. 
It was found that several characterized antibodies can bind their target 
antigen in eukaryotic cells in this two-hybrid format, and that this system is 
able to isolate intracellular binders from among sets of scFv that can bind 
antigen in vitro. 
Moreover, the application of this system to a library-selection scheme, in 
which a protein involved in Alzheimer’s disease was chosen for 
investigations, has lead to the selection of several specific and soluble 
antibody-fragments readily folded for intracellular application.  
The ability of this system to work in intracellular conditions and to provide 
specific binding quickly and economically, suggest that this approach can 
be used on a genome-wide scale to specifically knock-out each node of a 
protein network as identified from protein linkage maps and to understand 
the connections of large networks of interacting proteins. 
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